Vagus nerve ear acupuncture point

Vagus nerve ear acupuncture point DEFAULT

Current Directions in the Auricular Vagus Nerve Stimulation I &#x; A Physiological Perspective

Introduction

Bioelectronic medicine progressively comes into focus as a non-pharmaceutical treatment option for various diseases. Here neuromodulation of the vagus nerve (VN), known also as wandering or pneumogastric nerve, gained a special interest in recent years.

This review aims to summarize the contemporary views on the electrical stimulation of the auricular VN (aVNS) as a promising electroceutical therapy in humans. Catalysts were the first two international workshops on aVNS in Warsaw (February 16, ) and Vienna (October 26 and 27, ) within the scope of EU COST Action European network for innovative uses of EMFs in biomedical applications (BM). In particular, the present review summarizes and discusses the physiological role of VN including a biology-driven rationale for aVNS, backed up by experimental and clinical data. A focused review on technical issues, modeling concepts, regulatory requirements, and novel architectures of aVNS paradigms is provided in our accompanying article (Kaniusas et al., ).

We start with biophysical principles underlying aVNS and continue with modulation of different body functions while including experimental data in animals and clinical data in humans. Future directions of aVNS are identified to complement this review.

Vagus Nerve

The vagus nerve is the 10th cranial nerve that starts at the brainstem with two bilateral branches, and widely meanders and loops within the neck, thorax and abdomen (Trepel, ). VN is composed out of myelinated A and B fibers as well as non-myelinated C fibers. VN establishes a mutual connection between the brain and major body structures as pharynx, larynx, trachea, heart, aorta, lungs, and the entire gastrointestinal tract including esophagus, stomach, liver, pancreas, and spleen (Berthoud and Neuhuber, ; Standring, ). These widespread projections of VN imply its involvement in many functions of the body&#x;s autonomic nervous system (ANS). The activity of VN is proportionally associated with health, wellbeing, relaxation, and even emotions like empathy, whereas it is negatively associated with risk factors such as morbidity, mortality, and stress (Thayer et al., ; Zulfiqar et al., ). VN thus plays a crucial role in determining brain-body interactions (de Lartigue, ). These manifold interactions &#x; as best exaggerated in Clancy et al. () as My function&#x;s almost anything, and vagus is my name &#x; naturally cause increasing interest in artificial VN stimulation for therapeutic purposes. VN is considered as a major nerve and thus mediator of the parasympathetic section of ANS, whereas the vagal tone activates the parasympathetic nervous system (Olshansky et al., ; Barella et al., ).

Most VN fibers (about 80%) are afferent sensory fibers carrying somatic and visceral information to the brainstem and thus providing a unique entrance to the brain (Berthoud and Neuhuber, ; Groves and Brown, ). In particular, visceral and cranial homeostatic sensory activity is mediated by input from VN (and other nerves) to the nucleus of the solitary tract (NTS) in the lower medulla. As shown in Figure 1A, most of afferent fibers of VN end in NTS, e.g., for visceral, taste, heart, and aorta afferents, while other afferents terminate in the nucleus spinalis of the trigeminal nerve, e.g., for larynx and pharynx afferents.

www.frontiersin.org

Figure 1. Natural sensory innervation of the auricle versus its artificial stimulation. (A) The vagus nerve (VN) connects the brain with most of the organs within the thorax and abdomen. Afferent auricular branches (aVN) leave the cervical VN at the level of the jugular ganglion just outside the cranium and innervate the rather central regions of the pinna of the outer ear (Peuker and Filler, ). (B) Electric stimulation of aVN endings with needle electrodes located within these central regions. NTS, nucleus of the solitary tract; NSNT, nucleus spinalis of the trigeminal nerve; NA, nucleus ambiguous; DMN, dorsal motor nucleus. This figure and figure caption was originally published in the sister manuscript to this review (Kaniusas et al., ), which was published in Frontiers of Neuroscience under the creative commons attribution license CC BY

The rest of VN fibers (about 20%) are efferent visceromotor fibers governing neurogenic, myogenic, and endocrine actions within end organs. These motor fibers originate in the nucleus ambiguous (for muscle innervation of the pharynx and larynx) and in the dorsal motor nucleus (to supply heart, lungs, esophagus, and stomach), as illustrated in Figure 1A. For instance, the right VN is more closely associated with the cardiac atria and innervates the sinoatrial node controlling the heart rate while the left VN is rather associated with the ventricles of the heart and innervates the atrioventricular node controlling the contraction force (Guiraud et al., ).

Considering our focus on vagus nerve stimulation (VNS), VN connects specific sensors and effectors in the periphery with the central nervous system. Mediated connections of VN &#x; within reach by several synaptic connections &#x; include projections to hypothalamus and cortex as higher brain regions, thus allowing modulative access of VN to subcortical and cortical brain areas (Berthoud and Neuhuber, ). Therefore, signals generated in VN have the potential to affect a broad range of basic brain functions and thus to affect the entire organism in terms of its protection.

Sensory Functions

Since VN is mainly a sensory nerve, it essentially relays biofeedback to the brain, which originates in mechanoreceptors, chemoreceptors, thermoreceptors, and osmoreceptors spread throughout the whole body (Berthoud and Neuhuber, ; Szekely, ; Williams et al., ). Most afferent VN endings are polymodal responding to a variety of stimuli. Here a direct activation of free nerve endings of the afferent VN, so-called primary sensing cells with embedded receptors in the nerve membrane (Kaniusas, ), are likely to be involved; e.g., for the sense of pain. In addition, an indirect activation of free endings of the afferent VN is given through synaptically connected specialized cells, so-called secondary sensing cells, e.g., for the sense of taste (de Lartigue and Diepenbroek, ).

To give a few examples, venous baroreceptors (mechano- receptors) connect to the afferent VN for blood volume control. Arterial baroreceptors in the aortic arch relay blood pressure via the afferent VN to the brainstem and thus serve as feedback for the short-term control of the arterial blood pressure (baroreflex). Mechanoreceptors and chemoreceptors in the stomach detect its luminal contents and signal it via the afferent VN to the brain for the satiety/hunger response (Williams et al., ; Andermann and Lowell, ). Here the afferent VN fibers originate in the mucosa and muscle layers of the digestive tract. Pulmonary stretch is also conveyed via the afferent VN to the brain, whereas mechanoreceptors and chemoreceptors in the respiratory tract govern the cough reflex. Likewise, mechanical stimulation of the afferent VN receptors in the diaphragm seems to mediate the influence of paced breathing to the brainstem activity. Interestingly, the Valsalva maneuver, vomiting reflex, carotid sinus massage, and ocular compression can be intentionally used to alter VN activity (Clancy et al., ). The afferent VN receptors strongly connect enterocrine cells with the brain (Han et al., ) and link this axis to reward sensitivity (Kaelberer et al., ).

The afferent VN carries also nociceptive fibers for pain, i.e., sensing extremes in temperature, pressure, or chemicals with high-threshold receptors. For instance, tearing or burning sensations related to irritation of lower airways are transmitted mainly through VN afferents. Further, a noxious gastric distention results in the vagally mediated excitation of NTS, whereas cardiac ischemia and pain are also mediated by VN receptors (Berthoud and Neuhuber, ).

Body Control via Sensory Functions

Activation of vagal afferents elicits efferent parasympathetic activation and sympathetic inhibition, like in the baroreflex (Karemaker, ). Therefore, a negative inhibitory feedback is provided by VN receptors to otherwise feed-forward sympatho-excitatory activation. As shown in Figure 2A, sensory VN fibers establish feedback-based control loops with their, in general, non-linear dynamics. However, since many organs such as the heart are innervated by both sympathetic and parasympathetic fibers, it is more precise to speak of the parallel control by both systems than to stress the antagonistic actions of parasympathetic and sympathetic systems (Olshansky et al., ; Karemaker, ).

www.frontiersin.org

Figure 2. Brain modulation via electrical stimulation of auricular vagus nerve (aVN) endings. (A) Intact feedback-loop which is composed out of efferent VN fibers (controlling different organs and functions) and afferent VN fibers (carrying sensory information back to the brain) for proper control of bodily organs and functions. (B) Different diseases may lead to a lost or impaired afferent feedback to the brain (e.g., due to neurodegeneration or maladaptive plasticity), which makes it impossible for the brain (the control station of the body) to adapt to changes in organs, functions, and/or environmental factors. (C) As a hypothesis, stimulation of aVN fibers substitutes the lost or impaired afferent feedback to the brain while inducing systemic regeneration processes. These processes, in turn, may lead to sustainable recovery of controlled organs and functions as well as recovery of the relevant sensory feedback-loop.

Sensory fibers in VN provide an excellent opportunity for the body to detect its homeostasis in the periphery (e.g., immune-related events) and then to generate appropriate neurogenic, myogenic, endocrine, and behavioral responses. These responses involve typically closed-loop reflex pathways along efferent and afferent pathways (Figure 2A). Central integration and processing of sensory information and the associated generation of motor output take place in the brain. Prominent examples are thermo-regulation, immune-regulation, and blood pressure control of the body.

For instance, increased arterial blood pressure (hypertension) stimulates baroreceptors in the aortic arch, signaling via the afferent VN to the brainstem. The brain, especially, NTS inhibits reflexively the sympathetic outflow to the heart and periphery in response to hypertension, whereas the stroke volume and the total peripheral resistance decrease, respectively. The parasympathetic outflow via efferent VN fibers is reflexively accelerated, slowing the heartbeat via the efferent VN connection to the sinoatrial node of the heart. Consequently, the blood pressure drops and thus normalizes. One can experience this vagal-mediated decrease in the heart rate through gentle rubbing on the vagus nerve via the carotid sinus, a technique known as carotid massage (Schweitzer and Teichholz, ; Lim et al., ).

Collectively, sensory VN seems to provide a powerful back door into the body, allowing you to hack the brain via artificial stimulation of sensory VN fibers, provided that the electrical language of nerves is spoken (Moore, ).

Why Auricular Vagus Nerve?

The external ear is the only place on the body where VN sends its only peripheral branch. In fact, the auricular branch of VN surfaces as the afferent auricular VN (aVN) and thus forms a cutaneous receptive field in the pinna of the ear. This field is susceptible to external stimuli in terms of peripheral nerve stimulation. In particular, aVN allows for an easy external access via electrical stimulation in terms of aVNS, which then connects directly and favorably the applied stimuli to the brainstem, as shown in Figure 1B. The brainstem even mediates aVNS input to higher brain regions via extensive projections to second and third order neurons within the brain (Mercante et al., b). The auricle and especially its aVN endings might become a powerful direct gateway to modulate various brain functions, offering the most affordable non-invasive manipulation of the central nervous system.

Even at about BC, the auricle&#x;s importance for acupuncture therapy was recognized as All the vessels congregate in the ear (Sator-Katzenschlager and Michalek-Sauberer, ). Current evidence suggests that even antinociceptive effects of auricular acupuncture are mediated by the stimulation of aVN (Usichenko et al., ).

Auricular vagus nerve is also known as Arnold&#x;s or Alderman&#x;s nerve (Nomura and Mizuno, ). It leaves the cervical VN at the level of the jugular ganglion where aVN have their bodies of the sensory ganglionic neurons, just outside the cranium. aVN endings provide the sensory innervation of specific regions of the external ear (Alvord and Farmer, ; Kandel et al., ; Peuker and Filler, ; He et al., ). As illustrated in Figure 1A, the middle region of the pinna, the central concha, is mostly innervated by aVN, whereas aVN was found in % of cases in cymba concha (Peuker and Filler, ). Other ear regions such as antihelix, cavity of concha, tragus, crus of helix, and crura of antihelix were found to be partly but non-exclusively innervated by aVN in 73, 45, 45, 20, and 9% of cases, respectively (Peuker and Filler, ). aVN is composed out of myelinated Aβ fibers (fibers with the diameter 7&#x;10 μm comprise about 20% of the total myelinated aVN axons with about myelinated axons per auricle), myelinated Aδ fibers (fibers with the diameter 2&#x;5 μm comprise about 50% of the total myelinated aVN axons) (Safi et al., ), and non-myelinated C fibers (Standring, ).

Besides aVN endings, the ear contains endings of non-vagal cervical and cranial nerves such as the great auricular nerve (e.g., present in the ear lobe), the auriculotemporal nerve (e.g., the branch of the trigeminal nerve located in the spine of helix), and the lesser occipital nerve (e.g., the upper third of the medial surface of the auricle) (Peuker and Filler, ). From an anatomical point of view, all nerve fibers in the auricle run between the ear cartilage and skin in a depth of 1&#x; mm (Bermejo et al., ). From a functional point of view, different physiological effects can be expected when stimulating locally different areas in the ear. For instance, variable intensity of induced autonomic changes was shown as a function of the area of stimulation in rats (Gao et al., ), whereas a significantly stronger activation of the NTS was proven when the cymba concha region was electrically stimulated in humans compared to sham stimulation and other auricular regions (Yakunina et al., ).

Auricular vagus nerve stimulation recruits sensory aVN fibers and thus mimics/projects sensory input to the brainstem in terms of neuromodulation, forming the so-called auriculo-vagal afferent pathway (He et al., ). Since aVNS projects directly to NTS (Figure 1A), both ANS and the central nervous system are modulated by aVNS. Consequently, since ANS, composed out of sympathetic and parasympathetic branches, governs systemic parameters of cardiovascular, respiratory, and immunological functions to stay within their homeostatic limits and, on the other hand, aVNS modulates the parasympathetic auricular branch, aVNS effects on the body can be expected to be systemic.

Systemic effects affect multiple physiological functions and are not specifically targeted to a particular organ or an isolated function. For instance, the sympathovagal balance &#x; as a systemic parameter of the body &#x; can be modulated for therapeutic reasons. In line with the aforementioned inhibitory effects of vagal receptors, systemic effects of aVNS can expected to be mostly from the sympatho-inhibitory origin (Deuchars et al., ). As illustrated in Figure 2A, aVNS modulates the biofeedback line to the brain so that this modulation shapes closed-loop reflex pathways, in analogy with neurobiological models from De Couck et al. (). Therefore, once again, diverse systemic effects of aVNS can be expected on the entire organism.

From an evolutionary developmental perspective, aVN is all that remains of a more extensive embryonic nerve which supplies the first branchial arch and is supposed to be the last phylogenetic remnant of the nerve innervating the lateral line organs in fish and amphibia (He et al., ). Interestingly, the sensory auricular nerve endings (including aVN) in mammals may have evolved from the mandibular/jaw area in the course of the evolutionary transition when post-dentary jaw elements moved to the cranium as auditory ossicles (Meng et al., ). This evolutionary development may justify some current complex pathways of aVN action in the pharynx area and may shed some light on the physiological relevance of aVN endings today.

Vagus Nerve Stimulation &#x; From Biophysics to Animal and to Human Data

Auricular vagus nerve stimulation is a peripheral, non-pharmacological, and minimally invasive neuromodulation technique, altering signal processing in the central nervous system, activating reflex circuitries, exploiting brain plasticity for different therapeutic purposes, and thus affecting profoundly different areas of the brain, as described below. The broad range of brain versus periphery projections of VN and its corresponding functions suggest a large variety of disorders possibly indicated for aVNS therapy in humans, whereas these disorders share common features related to the protective function of VN. This simple peripheral technique of aVNS gains access to central pathways of the brain. Due to systemic effects of aVNS &#x; and, in general, of any VNS &#x; many different biophysical mechanisms have been found to be modulated, including ANS affecting the whole organism. Though the exact mechanisms of aVNS and VNS remain to be elucidated, the following neurophysiological evidence and modulation of different body functions are based on strong hypothesis derived from experimental animal and clinical human data.

With the critical assumption that observed neurophysiological effects of aVNS and VNS may be considered as being similar (see below), here we review both implanted VNS and non-implanted minimally invasive aVNS in animal models. In fact, tightly controlled settings in experimental animal studies allow for potentially more consistent findings in bio-physiological basic mechanisms behind aVNS than human studies. In addition, observed effects in animals indicate potential applications of aVNS in humans.

In the reviewed human studies, we focus on clinical evidence of transcutaneous and percutaneous aVNS, whereas a lot of populations have been found to benefit from aVNS therapy, as summarized in Figure 3. Although randomized clinical trials on aVNS are accumulating, a lot of them are preliminary case studies. For human studies with potential clinical applications, we differentiate explicitly between clinical trials, case studies, and reviews to qualify the strength of statement. Studies on auricular electroacupuncture or peripheral nerve stimulation are also included if stimulation electrodes were located in vagally innervated regions of the auricle (Figure 1A). Therefore, applications of the implanted VNS in humans &#x; the therapy which became established during the past 20 years (Beekwilder and Beems, ) &#x; are excluded in order to focus on aVNS only.

www.frontiersin.org

Figure 3. Reported clinical applications of the auricular vagus nerve stimulation (aVNS) in humans. The total area of the pie chart indicates the total number of publications reviewed, whereas individual pieces refer to the respective numbers of clinical trials, case studies, and reviews.

Neurophysiological Evidence &#x; Modulation of Brain Function, Reflex Loops, and Brain Chemistry

Peripheral aVNS modulates various central brain structures involved in autonomic control and in motor control, especially via projections from NTS and nucleus spinalis of the trigeminal nerve, whereas the main therapeutic target is NTS (Figure 1A). In the following, we summarize different methods used to validate this modulation.

(i) Functional magnetic resonance imaging has shown specific modulation of various brain structures following aVNS. These structures include the brainstem and its nuclei NTS and nucleus spinalis of the trigeminal nerve (Chae et al., ; Kraus et al., , ; Dietrich et al., ), and are mostly associated with the higher order relay of afferent (visceral and somatic) VN pathways and networks (Badran et al., ). These modulated structures are involved in autonomic regulation, alertness, mood, and well-being control. The brain activation patterns in aVNS were shown to be similar to those during the implanted cervical VNS (Beekwilder and Beems, ), indicating favorably similar therapeutic effects of non-invasive and invasive VNS (Mercante et al., b). Most interestingly, activation and deactivation patterns of the brain in response to aVNS over-lasted the effective duration of the stimulation &#x; e.g., by as much as 11 min after cessation of cymba concha stimulation (Frangos et al., ) &#x; providing support for the hypothesis of long-lasting sustainable effects of aVNS.

(ii) Evoked far-field brainstem potentials have been reported in response to aVNS since activation of vagal afferents evokes vagus somatosensory potentials in the brain (Fallgatter et al., ; Polak et al., ). In particular, these potentials reflect the postsynaptic brainstem activity and thus can be regarded as a measure for the brain modulation following aVNS. These brainstem potentials presumably originate in vagal nuclei such as NTS (Fallgatter et al., ; Polak et al., ) and, again, are similar to evoked potentials from implanted VNS (Nonis et al., ). Interestingly, potentials show longer latencies in the elderly than the younger participants (Fallgatter et al., ).

(iii) Extracellular recordings in the brain have shown that the percutaneous aVNS decreases spontaneous firing of neurons in the central nervous system &#x; namely, in the central nucleus of the amygdala &#x; by about 50% (Babygirija et al., ), which confirms inhibitory effects of aVNS. For instance, the suppression of epileptiform activity was observed via activated firing of NTS neurons in response to aVNS (He et al., ). Inhibitory effects of VNS were shown in animal models (Lockard et al., ). In particular, motor activity and brainstem neuronal activity were inhibited in cats, as well as the tail-flick reflex in rats. Here a consistent animal alertness was commonly used to find the stimulation threshold indicating inhibitory effects and moreover to ensure comfort and safety of animals.

(iv) Significant changes in the resting electroencephalogram, especially, activation of the mediofrontal theta band, have been observed in response to the implanted VNS (Bonaz and Pellissier, ).

(v) Transcranial magnetic stimulation was used to prove increased intracortical inhibition in response to aVNS, most likely due to increased GABAergic activity (Capone et al., ).

Auricular vagus nerve stimulation has the potential to improve neuronal plasticity provided that plasticity is maladaptive (Clancy et al., ; Lehtimaki et al., ). For instance, the invasive VNS paired with auditory stimuli were shown to reverse pathological changes of the cortex in a rat model of tinnitus (Engineer et al., ). Since the intact brain plasticity follows different time scales, from quite fast changes within seconds up to slow changes within weeks up to 1 year, aVNS effects can be expected to follow these time scales. In addition, artificial neuromodulation of VN positively affects impaired synchronicity of synaptic activities between and within brain regions as well as overly excited or even deficient reflexes involving central brain pathways (Oleson, ; Beekwilder and Beems, ). VNS and even aVNS may activate reflexes which inhibit maladaptive reflexes of neuromuscular disorders in humans (Kampusch et al., a) as well as may modulate nociceptive reflexes in rats, namely, facilitate them at low VNS intensities and inhibit at high intensities (Ren et al., , ). All these detrimental changes in the brain and reflexes are usually present in chronic diseases such as chronic pain or chronic muscle spasms, which are thus possible application fields of aVNS.

Figure 2B illustrates schematically how the sensory feedback to the brain is lost or impaired &#x; in contrast to intact feedback-loops from Figure 2A &#x; due to the aforementioned detrimental changes in the brain and reflexes, due to maladaptive plasticity and neurodegeneration. Since aVNS recruits sensory fibers to the brainstem (Figure 1), aVNS could be hypothetically expected to mimic the sensory feedback to the brain (Figure 2C), circumventing temporally a lost or impaired feedback. For instance, the invasive and selective stimulation of the cervical VN was used to mimic baroreceptor signals to lower the blood pressure in rats (Plachta et al., , ). In analogy, the baroreflex sensitivity was improved by aVNS in humans (Antonino et al., ), thus affecting processing of afferent signals in the brain. In addition, aVNS seems to have the potential to restore the missing or altered signaling of intestinal VN afferents (Guiraud et al., ).

More importantly, aVNS in Figure 2A could be hypothesized to be followed by sustainable regeneration mechanisms which re-establish the impaired sensory information flow to the brain, as a basis for systemic and sustainable treatment of disease via aVNS. The sustainability of aVNS was demonstrated not only on the brain level, as discussed above with respect to Frangos et al. (), but also on physiological level. For instance, the activation of the anti-inflammatory response required only a brief VNS stimulus and lasted for more than 24 h (Olofsson et al., ). A sustained antinociceptive effect of aVNS was observed in pain-related gastrointestinal disorders for an extended period of 9 weeks after 3 weeks of treatment (Kovacic et al., ), as well as in chronic low back pain for a 3 months follow-up after 6 weeks of treatment (Sator-Katzenschlager et al., ).

In response to VNS, endogenous opioid neuropeptides (endorphins) are released in the central nervous system as well as various neurotransmitters (enkephalins and substance P). The release alters properties of neuron membranes, the neuron&#x;s response to synaptic events, and thus alters excitation or inhibition of neuron firing. Consequently, neuronal networks can be potentially reprogramed by VNS, in line with the discussed neuroplasticity. Interestingly, the release of neuropeptides due to aVNS seems to depend on the stimulation frequency (Sator-Katzenschlager and Michalek-Sauberer, ). A relatively low frequency of 2 Hz accelerates the release of enkephalin, β-endorphin, and endomorphin. In contrast, a high frequency of Hz selectively increases the release of dynorphin.

Vagus nerve stimulation seems to modulate serotonergic, noradrenergic, and endorphinergic pathways in different brain regions by the relay projections of the vagal afferent nuclei. The associated release of serotonin, norepinephrine, and endogenous opioids is increased while modulating chemically the nociceptive processing in the brain (Lockard et al., ; Oleson, ; Lehtimaki et al., ), the mood and anxiety control, and the pathophysiology of depression (Beekwilder and Beems, ; Chakravarthy et al., ; Conway and Xiong, ; Mercante et al., b). Even aVNS increased norepinephrine levels in rats (Li et al., b). Increased release of noradrenaline in the brain seems to follow VNS, as well as increased amounts of the inhibitory transmitter GABA in the cerebrospinal fluid (Groves and Brown, ) and NTS (Mercante et al., b), which potentially leads to VNS-mediated seizure reduction (Clancy et al., ) and antidepressant effect (Mercante et al., b). VNS inhibits excitatory glutamate release (Chen et al., c). VNS increases the release of neurotrophic factors as well as stimulates cellular proliferation and neurogenesis in the brain, which have been associated not only with antidepressant effects but also neuronal plasticity, memory, learning and cognitive processes (Mercante et al., b).

In fact, the actual stimulation pathway of aVNS is highly indirect with respect to the distant pathological organ or addressed functions of the body, since aVN has a transmitting but not a processing function. In particular, the stimulation pathway is circuitous. The pathway of the therapeutic electric stimuli starts with action impulses traveling from the peripheral somatosensory aVN endings in the auricle to the brainstem and then to higher order brain structures. Then, the pathway goes either from cranial nerves to the correspondent region of the body or, in analogy, from the brain to the spinal cord and then from spinal nerves to the target body&#x;s region. Both somatic efferent arms (see section Pain &#x; Experimental Evidence ) and autonomic efferent arms (see section Modulation of Autonomic Function ) can be expected to be modulated. Distant targets are thus affected via neurological networks or reflexes.

Epilepsy

Both VNS and aVNS reduced epileptic seizure activity in rats (He et al., ) via activated firing of neurons in NTS (He et al., ). Authors in Zagon and Kemeny () suggest a vagally mediated hyperpolarization and thus reduced excitability of cortical neurons that otherwise would be involved in propagation of seizures. VNS decorrelated cortical synchrony and rhythmicity in rats indicating a potentially reduced seizure activity (Nichols et al., ). The period of protection from seizure activity persisted beyond the stimulation period (Schachter and Saper, ), whereas VNS and aVNS showed similar durations of the anti-seizure effect (Ellrich, ).

In humans, aVNS reduced seizure frequency in epilepsy as well as the intensity and duration of seizures, as shown in clinical trials (Rong et al., ; Bauer et al., ), a case series (Stefan et al., ), and reviewed in Beekwilder and Beems () and Shiozawa et al. (). The required dosage of antiepileptic drugs was also reduced (Beekwilder and Beems, ).

Depression

Melatonin secretion in response to aVNS ameliorated the innate depressive behavior in diabetic rats (Li et al., ). The antidepressant effect of aVNS was also demonstrated in rats with suggested cardio-inhibitory effects, possibly mediated via the normalization of the hypothalamic-pituitary-adrenal axis hyperactivity in major depression (Liu et al., ).

In humans, clinical improvement of depression was shown when treated with the transcutaneous aVNS, whereas depression scores as well as remission rates improved, see clinical trials (Kraus et al., ; Hein et al., ; Fang et al., ; Rong et al., ) and a review (Shiozawa et al., ).

Stroke

Auricular vagus nerve stimulation reduced significantly the infarct volume and improved neurological scores after cerebral ischemia in rats (Ay et al., ), whereas only an insignificant reduction in the lesion size was observed after ischemic stroke in rats (Hays et al., ). aVNS improved neurobehavioral recovery and upregulated cerebral growth differentiation factor 11 &#x; a rejuvenation factor participating in brain angiogenesis almost in parallel to neurogenesis after stroke &#x; in cerebral ischemia/reperfusion rats (Ma et al., ). The transcutaneous aVNS in humans was shown to improve rehabilitation in stroke according to a clinical trial in Capone et al. (). These reports indicate aVNS as a potential therapy target for stroke.

Invasive VNS paired with rehabilitative training significantly improved recovery of forelimb function in rats after both intracerebral hemorrhage (Hays et al., ) and ischemic stroke within the motor cortex (Hays et al., ). Here the sensory inflow along VN potentially provides an associative component to neuronal plasticity in the brain, which enhances plasticity. This may indicate a potential use of aVNS paired with movements to improve cortical representation of movements in the treatment of movement disorders, including the rehabilitation of stroke patients (Porter et al., ).

Other Disorders

Vagus nerve stimulation improved recovery after traumatic brain injury in rats, based potentially on enhanced neural plasticity and enhanced norepinephrine release (Smith et al., ). VNS has shown efficacy in enhancing memory storage processes, as mediated by stimulation of VN afferents in rats (Clark et al., ). Furthermore, VNS facilitated visceral pain-related emotional affective memory (Zhang et al., ) and enhanced the extinction of conditioned fear when paired with extinction training (Peña et al., ) in rats.

In humans, the transcutaneous aVNS is a promising treatment method for autism spectrum disorders and a lot of other psychiatric disorders, as reviewed in Cimpianu et al. () and Jin and Kong (), respectively. However, aVNS failed to improve schizophrenia symptoms, as recognized by a clinical trial in Hasan et al. ().

In addition, positive effects in Alzheimer&#x;s disease can also be potentially expected because decreased norepinephrine levels are raised by VNS, the levels being essential in maintaining adequate beta amyloid clearance and thus preventing Alzheimer (Beekwilder and Beems, ). The neuroprotective role of aVNS was shown in a mouse model of Alzheimer disease (Kaczmarczyk et al., ). Interestingly, evoked far-field brainstem potentials after aVNS have been proposed to be used for an early diagnosis of dementias and Alzheimer&#x;s disease, see clinical study in Polak et al. (). In particular, latencies of these potentials increase in disease due to degeneration of nervous structures of vagal parasympathetic nuclei.

Modulation of Nociceptive Processing

The central sensitization represents enhanced excitability of nociceptive pathways due to maladaptive plasticity of the central nervous system [e.g., in the superficial dorsal horn (Todd, )] in response to hyperactivity, inflammation, and neural injury (Latremoliere and Woolf, ). This sensitization seems to be a key factor to potentiation in pain sensibility in acute and chronic pain while recruiting previously subthreshold synaptic inputs to excitatory nociceptive pathways. Hyperalgesia can also be produced by illness-inducing agents such as bacterial cell wall endotoxin lipopolysaccharide, whereas these agents activate VN afferents in terms of immunosensation, i.e., sensation of immune-relevant substances (Watkins et al., ). The inhibitory and desynchronizing actions of VNS together with enhanced brain plasticity and activated serotonergic pathways (see section Neurophysiological Evidence &#x; Modulation of Brain Function, Reflex Loops, and Brain Chemistry ), as well as anti-inflammatory effects of VNS (see section Modulation of Inflammation ), all can be hypothesized to counteract the maladaptive plasticity and inflammation of the central sensitization and thus to counteract pain hypersensitivity. These actions of VNS may potentially contribute to antinociceptive aVNS effects in hyperalgesia, with the aforementioned assumption of similar neurophysiological effects of VNS and aVNS (Beekwilder and Beems, ; Mercante et al., b).

Gating mechanisms may become indirectly modulated by aVNS for antinociception, as related to the well-known concordant paresthesia. That is, pain mediated by Aδ and/or C afferents is alleviated by touch or by a simultaneous activation of tactile Aβ afferents from a homotopic site (Ellrich and Lamp, ). For instance, hitting a finger can induce pain which can be compensated by rubbing fingers. In particular, the activation of Aβ fibers can inhibit transmission of nociceptive signals in that excited Aβ fibers inhibit presynaptic terminals of Aδ and/or C fibers (Sandkühler, ), which is known as activation of inhibitory pain control systems. This leads to wind-down of pain-induced changes in the signal transduction within the spinal cord (Sandkühler, ). The electrophysiological data provide evidence that electric stimulation of peripheral Aβ fibers reliably suppresses Aδ fiber nociceptive processing in human volunteers (Ellrich and Lamp, ).

Since the stimulated Aβ afferents in the auricle and nociceptive signals along Aδ and/or C afferents do not originate in homotopic sites, we cannot expect a direct activation of gating mechanisms on the spinal level via aVNS. However, since aVN projects via NTS to numerous other brainstem complexes (Nomura and Mizuno, ) mutually interacting with spinal regions involved in pain processing (e.g., dorsal horn neurons), an indirect modulation of gating mechanisms can be hypothesized. In addition, aVNS may co-recruit non-vagal auricular nerves (e.g., the great auricular nerve) which end in spinal regions (Mahadi et al., ) and thus may directly interfere with gating mechanisms there.

Gating may also refer to blockage of nociceptive signals from ascending peripheral nerves to the brain by descending impulses from the brain (Oleson, ). Not only ascending nociceptive stimuli are disrupted but also descending nociceptive signals into the gray matter of the dorsal horn of the spinal column are mitigated (Roberts et al., ).

In addition, encephalin-containing interneurons within the spine are proposed to be activated resulting in the inhibition of conduction of pain signals to the brain (Sator-Katzenschlager and Michalek-Sauberer, ). Single neuron studies reveal that activation of vagal afferents mostly inhibits nociceptive neurons in the spinal cord in response to noxious stimuli, especially at greater intensities of VNS; e.g., 77% of observed spinothalamic tract neurons were inhibited (Ren et al., ). Interestingly, the effective inhibition of nociceptive processing in humans can even outlast conditioning electric stimuli (Ellrich and Lamp, ), which may theoretically lead to short-term and even long-term afferent-induced analgesia (Sandkühler, ) in response to aVNS (Sator-Katzenschlager et al., ).

For effective antinociception using peripheral nerve stimulation, a non-painful stimulus is required to excite rapidly conducting thick myelinated Aβ fibers but not nociceptive slowly conducting thin myelinated Aδ and thin non-myelinated C fibers. Please note that excitation thresholds of Aβ fibers are lower than those of Aδ and C fibers because both myelinization and increasing fiber thickness reduce their threshold (Kaniusas, ). Therefore, the nociceptive threshold in different nerves was found to be 5&#x;7 times larger than the detection threshold, whereas near maximal activation of Aβ fibers was suggested to be only 4 times the detection threshold (Ellrich and Lamp, ). For comparison, the activity of the least excitable C fiber can be evoked by stimuli with intensities 15&#x;20 times the detection threshold (Ellrich and Lamp, ); in line with (Guiraud et al., ) stating that the activation threshold of C fibers is 10&#x; times greater than that of A fibers.

However, the requirement of the recruitment of non-C-fibers for antinociception in peripheral nerve stimulation contrasts with experimental investigations on the invasive VNS and thus potentially indicates different mechanisms of action in aVNS and in VNS. That is, single neuron studies in rats (Ren et al., , ) and targeted pharmacological blunting of C-fibers (Ren et al., ) indicate that a low-intensity VNS accelerates discharges of nociceptive neurons in the spine, facilitates nociceptive reflexes and thus produces pronociception, and suggests activation of low-threshold myelinated non-C-fibers of the stimulated afferent VN. In contrast, a high-intensity VNS yields opposite effects of antinociception due to the activation of high-threshold C-fibers but not low-threshold myelinated non-C-fibers of the afferent VN (Ren et al., ).

In general, stimulated VN afferents can exert both inhibitory and excitatory modulation of the nociceptive processing in spinal and supraspinal regions, in central and peripheral pain pathways (Berthoud and Neuhuber, ; Busch et al., ; Napadow et al., ). Low stimulus intensities applied in the afferent invasive stimulation of VN tend to induce pronociception (Ren et al., ; Ness et al., ) while high intensities &#x; still non-noxious but perceivable stimuli &#x; tend to induce antinociception (Chakravarthy et al., ). In line with (Randich and Gebhart, ), antinociceptive inhibiting effects of VNS begin to counteract pronociceptive facilitatory influences of VNS with increasing VNS intensity. However, some controversy exists concerning pronociception in response to the afferent stimulation of VN (Busch et al., ). Some human subjects with implanted VNS have even shown U-shaped thermal pain thresholds with increasing VNS intensity (Ness et al., ). Authors in Laqua et al. () report both antinociception and pronociception in response to aVNS in about 70 and 30% of healthy subjects, respectively, accounting this to individual sensitivity. As a hypothesis supported by the authors, low and high intensity VNS may potentially activate different circuits in the brainstem.

Furthermore, stimulation of vagal afferents with the subsequent neuromodulation of NTS (Figure 1A) is hypothesized to underlie the antinociceptive effects of VNS (Napadow et al., ). This is because NTS acts as an integrating station for nociceptive afferent stimuli (Boscan et al., ) and as a relay station and inputs to higher brain regions, which process and modulate different aspects of pain (Saper, ). Furthermore, spinal regions processing pain project to NTS (Todd, ), such as the dorsal horn neurons (Mahadi et al., ). For instance, an electrical stimulation of NTS was shown to inhibit nociceptive responses at the spinal cord level (Du and Zhou, ), whereas a local anesthetic block of NTS eliminated the inhibitory effect of VN stimulation on the nociceptive tail flick reflex in rats (Randich and Aicher, ). Authors in Napadow et al. () have shown less antinociceptive effects in an auricular non-VN stimulation as compared to the auricular VN stimulation mediated by NTS.

Pain &#x; Experimental Evidence

In animals, VNS attenuated heat-induced and formalin-induced pain in rats (Bohotin et al., ). aVNS increased paw withdrawal threshold in rats and attenuated baseline firing of neurons in the central nucleus of the amygdala and spinal cord neurons by about 50%, which may account for the modulation of pain responses (Babygirija et al., ). VNS was shown to inhibit cortical spreading depression, a propagating wave of depolarization that underlies migraine aura and thus triggers headache in rats (Chen et al., c). Interestingly, the non-invasive VNS on the neck demonstrated the potential to alleviate trigeminal allodynia in rats (Oshinsky et al., ). This type of VNS decreased levels of the extracellular glutamate in the trigeminal nucleus caudalis, a neurotransmitter that increases with trigeminal pain.

In humans, the electrical stimulation of auricular regions including aVN increased electrical pain thresholds by 30&#x;50% in about half of the studied healthy subjects (Johnson et al., ), increased mechanical and pressure pain thresholds (Beekwilder and Beems, ; Busch et al., ), as well as increased pressure pain thresholds and decreased pain ratings under sustained application of painful heat (Ellrich et al., ). Once again, predominant inhibitory effects of aVNS are highlighted by these cited studies.

Pain &#x; Clinical Evidence

Antinociceptive effects of aVNS were shown in numerous clinical trials: chronic cervical pain (Sator-Katzenschlager et al., ), chronic low-back pain (Sator-Katzenschlager et al., ), acute pain during in vitro fertilization (Sator-Katzenschlager et al., ), postoperative pain after laparoscopic nephrectomy (Likar et al., ), postoperative pain after tonsillectomy (Kager et al., ) &#x; as also supported by a review (Cho et al., ) &#x; postoperative pain after hysterectomy (Tsang et al., ), headache syndrome (Busch et al., ), high-frequency and chronic migraine (Straube et al., ), acute migraine (Garcia et al., ), chronic abdominal pain-related functional gastrointestinal disorders (Kovacic et al., ), and chronic pelvic pain (Napadow et al., ). A few case studies support antinociceptive effects of aVNS, namely, in postoperative pain (Szeles et al., ) &#x; as also supported by a review (Liu et al., ) &#x; chronic muscle pain in dystonia (Kampusch et al., a), pain in peripheral arterial occlusive disease (Payrits et al., ), pain in primary Raynaud&#x;s syndrome (Schlager et al., ), labor pain (Grünberger et al., ), and finally in diverse musculoskeletal pain disorders (unpublished data by our group in Vienna).

The percutaneous aVNS significantly reduced opioid intake, such as tramadol (Sator-Katzenschlager et al., , ), remifentanil (Sator-Katzenschlager et al., ), morphine-hydrochloride (Likar et al., ), naproxen and tramadol (Kager et al., ), all latter studies are clinical trials, and morphine, as reviewed in Liu et al. (). aVNS reduced anesthetic requirements in response to noxious electrical stimulation, as shown in a clinical trial (Greif et al., ) and reduced analgesic medication intake after abdominal and accident/trauma surgery, as shown by a case series in Szeles et al. ().

However, the percutaneous aVNS in the following clinical trials failed to show reduced acute pain and reduced analgesic consumption in the perioperative setting of the third molar tooth extraction (Michalek-Sauberer et al., ), as well as aVNS failed to reduce postoperative pain and opioid consumption in women undergoing elective gynecological laparoscopy (Holzer et al., ).

In general, results for aVNS are controversial in acute pain but are rather consistent in chronic pain (Sator-Katzenschlager and Michalek-Sauberer, ). This suggests that aVNS may be rather a long-term adjunctive therapy for treating chronic pain than an acute treatment (Clancy et al., ). In fact, chronic pain and acute pain are two different processes. Acute pain is a physiological process with well-defined anatomical pathways underlying the perception of nociception. In contrast, chronic pain is a pathological state associated to the complex rewiring of circuitries of the central nervous system, reported as maladaptive plasticity (Colangelo et al., ).

Auricular vagus nerve stimulation decreased symptoms of acute opioid withdrawal &#x; related to heroin, methadone and others &#x; after just 1 h of stimulation and allowed for an effective transition to non-opioid assisted medication therapy in some patients, as illustrated by a retrospective case series in Miranda and Taca (). aVNS was shown to be associated with temporary relief of withdrawal symptoms in heroin-addicted subjects on and after treatment in the first 3 days, see a case series in Wen et al. ().

Modulation of Inflammation

Inflammation processes are governed through interrelated humoral and neural reflex pathways (Tracey, ; Miller and Raison, ). In particular, chronic inflammation is based on deregulation of metabolic and immune functions, whereas the imbalance between pro-inflammatory and anti-inflammatory cytokines seems to be decisive in disease progression (Neurath, ). Abnormal and chronic inflammation is implicated in, causes and advances, numerous wide-spread chronic diseases as diabetes mellitus and is, for example, a major hindering factor in effective neuroprotection in the brain, e.g., after stroke.

The vagus nerve provides a first-line defense against infection and inflammation in the periphery to restore homeostasis via conducting information to/from the brain to regulate the immune system. VN is a major component of the neuroendocrine-immune axis (Bonaz and Pellissier, ). For instance, even fever, as a brain-mediated response, is signaled to the brain via afferent VN responding to peripheral proinflammatory cytokines, in addition to blood-borne routes for the fever&#x;s signaling (Hansen et al., ).

The parasympathetic outflow along VN, i.e., activation of the parasympathetic system, has only anti-inflammatory effects. This was shown by the inverse relationship between VN-mediated parasympathetic markers of the heart rate variability (HRV) and inflammatory markers (Thayer and Fischer, ). In contrast, the sympathetic nervous system may have both pro-inflammatory and anti-inflammatory effects.

In general, VN is involved in mainly three reflex pathways with a clear anti-inflammatory role:

(i) The anti-inflammatory hypothalamic-pituitary-adrenal axis. Here afferent VN fibers sense the level and location of injury/infection in that pro-inflammatory cytokines and/or endotoxins activate VN endings. Somatotopic maps in NTS become activated. Consequently, special neurons in hypothalamus activate the release of hormone adreno-corticotrophin by the hypophysis, stimulating the release of glucocorticoids by the adrenal glands to decrease peripheral inflammation.

(ii) The anti-inflammatory vago-vagal reflex, known also as the cholinergic anti-inflammatory pathway (Borovikova et al., ; Tracey, ). Here infection-activated afferent VN fibers synapse with and generate an outflow along efferent VN fibers releasing acetylcholine at their synaptic endings. The acetylcholine binds to surface receptors of macrophages and suppresses the production and release of pro-inflammatory cytokines by these macrophages.

Interestingly, the tonic neural activity of this cholinergic anti-inflammatory pathway is essential because, when it is impaired, over-inflammation results with an unrestrained cytokine release damaging tissue (Mercante et al., a). From this perspective, VNS enhances the activity of immune-related neural circuits and confers protection of the human body.

(iii) The splenic sympathetic anti-inflammatory pathway. Here the infection-activated afferent VN yields outflow along the efferent VN which stimulates the adrenergic sympathetic nerve in the spleen, releasing norepinephrine at its endings. Then norepinephrine binds to splenic lymphocytes and leads to acetylcholine release by lymphocytes, whereas acetylcholine, in turn, inhibits the release of pro-inflammatory cytokines by splenic macrophages.

Thus, the innate immune system is subjected to a closed-loop reflex modulation via afferent VN fibers, as illustrated in Figure 2A, whereas the activity of the efferent VN maintains homeostasis by limiting pro-inflammatory responses and avoiding immunosuppression. For instance, the role of VN is proposed in informing the brain about peripheral inflammation related to coronary artery disease and in actively modulating the disease related inflammation (Gidron et al., ).

An artificial VNS has been shown to harness this natural reflex (Figure 2C). The modulation of VN results in decreased pro-inflammatory and increased anti-inflammatory cytokines, which is effective in suppression of over-inflammation, prevention of tissue injury, and improved survival. For instance, aVNS reduced pro-inflammatory cytokines, as shown in a clinical trial (Stavrakis et al., ), and increased norepinephrine levels, as reviewed in Beekwilder and Beems (), which supports anti-inflammatory aVNS effects.

In particular, VNS was shown to rebalance the working point of autonomic regulation of the immune system into a protective range avoiding pro-inflammatory responses and, on the other hand, avoiding immunosuppression (Tracey, ). Here the working point is defined as the magnitude of innate immune responses relative to the infection or injury stimulus. Chronic changes can unfavorably increase or decrease the working point with the resulting overshooting immune response (with tissue damage, sepsis, or even death) or immunosuppression (with secondary infections), respectively.

In animals, VNS had favorable effects on rheumatoid arthritis in rats (Koopman et al., ). VNS reduced surgery-induced intestinal inflammation and improved postoperative intestinal transit in mice, supporting the anti-inflammatory effect of VNS (Matteoli et al., ). In addition, VNS prevented the development of shock in rats through inhibited synthesis of the tumor necrosis factor (cytokines) (Borovikova et al., ). aVNS was shown to be efficient in mice with lethal endotoxemia or polymicrobial sepsis while reducing systemic tumor necrosis factor due to anti-inflammatory aVNS effects (Huston et al., ). aVNS suppressed lipopolysaccharide-induced inflammatory responses in endotoxemic rats through reduced pro-inflammatory cytokines, indicating that aVNS modulates the immune function through the cholinergic anti-inflammatory pathway (Zhao et al., ).

In humans, potential therapeutic applications of aVNS are related to chronic inflammatory conditions. These are rheumatoid arthritis, see a clinical trial in Becker (), inflammatory bowel disease (Crohn&#x;s disease, ulcerative colitis), and postoperative ileus in order to restore intestinal homeostasis, as reviewed in Tracey (), Marshall et al. (), and Bonaz and Pellissier ().

Modulation of Autonomic Function

Vagus nerve stimulation and aVNS are followed by a broad physiological multi-level response, as already outlined above. The stimulation leads to systemic autonomic effects in terms of the parasympathetic stimulation of the body (He et al., ). The antagonistic action of the activated parasympathetic system over the sympathetic is one of the expected therapeutic mechanisms of aVNS, as, for instance, reflected by estimation of the shift of the ANS activity toward parasympathetic dominance with reduced sympathetic contribution (Clancy et al., ; Kampusch et al., a).

That is, the sympathovagal balance &#x; or the activity of ANS (HRV, ; Billman et al., ) &#x; seems to improve in response to aVNS, as estimated by its standard measure, HRV (Gbaoui et al., ; Kaniusas et al., ; Kampusch et al., b; Gomolka et al., ). For instance, the parasympathetic tone can be estimated from HRV during respiration cycle (HRV, ). While a shift toward parasympathetic predominance was indicated in aVNS by a decreased ratio of low-frequency to high-frequency (LF/HF) components of HRV (Deuchars et al., ), muscle sympathetic nerve activity (derived by microneurography), as a marker for the total sympathetic outflow, decreased (Clancy et al., ). However, authors in De Couck et al. () and Antonino et al. () report on partly diverging results on HRV in response to aVNS.

Baseline values seem to have an influence on the autonomic response due to aVNS or VNS. For instance, a higher resting ratio LF/HF predicted its greater decrease during aVNS in healthy humans, implying that humans with higher sympathetic activity are subjected to a stronger aVNS effect (Clancy et al., ). However, the invasive VNS in epilepsy patients showed an inverse behavior, in that a higher parasympathetic activity, e.g., a higher HF level, led to a better therapeutic outcome of VNS (Liu et al., ).

Modulation of Metabolic Syndrome

Reduced activity of VN, especially, decreased parasympathetic and increased sympathetic activity, are hypothesized to underlie metabolic syndrome (De Couck et al., ). Therefore VNS and aVNS can be expected to reduce risks of metabolic syndrome that includes obesity, elevated glucose levels, diabetes, elevated blood pressure, and increased inflammation (Pavlov and Tracey, ).

In animals, VNS is associated with the weight loss, reduced fat mass, and decreased appetite (Sobocki et al., ; Browning, ; Banni et al., ). For instance, VNS decreased weight gain, food consumption, and sweet craving in adult obese minipigs in the context of morbid obesity (Val-Laillet et al., ; Cork, ). aVNS reduced body weight in rats and the amount of the white adipose tissue in viscera (Li et al., b), indicating an important role of VN in obesity management. Interestingly, an imbalance in ANS with predominant parasympathetic activity is suggested to cause obesity in rats (Barella et al., ). aVNS showed antidiabetic effects in rats through triggered secretion of melatonin involved in the regulation of glucose metabolism (Wang S. et al., ) and through reduced diabetic cellular injury (Mei et al., ). This is because VN is strongly involved in the glucose metabolism and insulin secretion (Barella et al., ).

In humans, a reduction of body weight and body mass index was observed in chronically obese females in response to aVNS in a clinical trial (Schukro et al., ). This is in line with a case series in Szeles et al. () in which the tendency of aVNS to reduce body weight and body mass index in adipose patients was observed. aVNS seems to affect appetite and satiety, inhibiting food intake and thus body weight (Schukro et al., ), as well as seems to affect glucose metabolism, as reviewed in Guiraud et al. (), with a potential impact on the reward system in the brain. Here the arcuate nucleus of the hypothalamus seems to play an important role in mediating the satiety in response to aVNS. In addition, aVNS and the associated raised serotonin levels have been shown to increase the tone in smooth muscles of the stomach and to enhance intestinal motility, suppressing appetite and contributing to the loss of body weight in obese people, as shown in a clinical trial in Richards and Marley () and reviewed in Ergene and Tan ().

In obese humans, the food signaling from the stomach is altered as a consequence of the reduced sensitivity of small intestinal VN afferents, so that aVNS seems to have the potential to restore this missing or altered signaling, as reviewed in Guiraud et al. (). This is in close analogy with the presented hypothesis in Figure 2.

Human studies indicate that low VN activity may underlie elevated glucose levels, whereas the transcutaneous aVNS significantly reduced the 2-h glucose tolerance (Huang et al., ). aVNS was shown to decrease glycated hemoglobin, blood urea nitrogen, serum creatinine, total cholesterol, and aspartate transaminase in patients with type 2 diabetes mellitus (Ju et al., ). Both referenced clinical trials show the potential of aVNS as a preventive treatment for pre-diabetes and as a complementary treatment of diabetes patients, respectively.

Modulation of Cardiovascular Effects

Vagus nerve stimulation effects &#x; especially effects of the parasympathetic modulation (Olshansky et al., ) &#x; on hemodynamic and cardiovascular control have been demonstrated (Ness et al., ; De Ferrari and Schwartz, ). However, consistent and significant changes in hemodynamic measures are usually absent at relatively low VNS intensities (e.g., below levels used for seizure control in humans) that are accompanied by pronociception, whereas hemodynamic measures are invariably altered at higher VNS intensities, especially at intensities with antinociceptive effects (Ness et al., ).

In animals, invasive VNS attenuated mean arterial blood pressure and reduced the number of arrhythmia episodes in hypertensive rats (Annoni et al., ), whereas it increased coronary flow in dogs (Tiedt and Religa, ). aVNS elicited cardiovascular responses in rats, characterized by a lowered blood pressure (Mahadi et al., ) and heart rate (Gao et al., ). Cardiovascular inhibition in rats due to aVNS was also shown in Gao et al. (), where reduced blood pressure and heart rate were paralleled by excitation of cardiac-related neurons in NTS. Similarly, vasodepressor and bradycardic effects of VNS were attenuated by local anesthetic blockage of NTS (Randich and Aicher, ). In dogs, the protective anti-arrhythmic role of VNS was shown in terms of preventing ventricular fibrillation after healed myocardial infarction (Vanoli et al., ). Interestingly, there are indications that a strong invasive VNS tends to facilitate atrial fibrillation, whereas a moderate VNS tends to inhibit atrial fibrillation without arrhythmogenic risks (Chen et al., a).

In humans, an increased cerebral blood flow was found in certain brain regions associated with afferent pathways of VN on acute activation of VNS, as shown in a clinical trial in Conway et al. (). aVNS was also reported to increase the velocity of cerebral blood flow in the supratrochlear artery and the middle cerebral artery in single patients (Széles and Litscher, ). aVNS decreased the carotid-femoral pulse wave velocity, as shown by a clinical trial in Hackl et al. ().

Auricular vagus nerve stimulation reduced the systolic blood pressure over time in patients with impaired glucose tolerance (Huang et al., ) and in patients with coronary artery disease (Zamotrinsky et al., ), both studies are clinical trials. The trial in Zamotrinsky et al. () showed markedly reduced sympathetic inflow to the heart in patients with coronary artery disease treated with the percutaneous aVNS. In general, aVNS decreased the heart rate, the systolic blood pressure, and improved the left ventricular diastolic filling and ejection fraction. A clinical trial in Badran et al. (b) demonstrated different changes in the heart rate in response to various aVNS parameters.

As shown in the following clinical trials in humans, aVNS suppressed atrial fibrillation in patients with paroxysmal atrial fibrillation (Stavrakis et al., ) and improved cardiac function in patients with coronary artery disease via upregulation of the protective heat shock proteins and reduction of the heart rate (Afanasiev et al., ). Furthermore, aVNS led to relief of anginal symptoms in coronary artery disease patients who underwent coronary artery bypass grafting operations, see a clinical trial in Zamotrinsky et al. (). Here aVNS resulted in diminution of biochemical myocardial signs of the disease, an increase in the heart&#x;s tolerance of operative reperfusion damage, and a reduced need for vasodilators.

Heart failure is another relevant condition for neuromodu-lation (Stavrakis and Po, ), characterized by a chronic autonomic imbalance with reduced VN activity and accelerated sympathetic activity (Olshansky et al., ; De Ferrari and Schwartz, ; Byku and Mann, ). In animals, VNS was proposed as a potential treatment of heart failure and angina pectoris (Bilgutay et al., ). VNS improved the long-term survival of rats with chronic heart failure through the prevention of pumping failure and cardiac remodeling (Li et al., ). VNS improved HRV and baroreflex sensitivity in a dog model of heart failure, in close association with a reduction in the expression of inflammatory cytokines and attenuated development of heart failure (Zhang et al., ). Beneficial effects of VNS may include anti-adrenergic effects at central and peripheral levels, anti-apoptotic effects, an increase in nitric oxide (NO), and anti-inflammatory effects (Olshansky et al., ; De Ferrari and Schwartz, ). In humans, aVNS acutely improved the spontaneous cardiac baroreflex sensitivity, as shown by a clinical trial (Antonino et al., ). A wealth of clinical studies shows that increased vagal activity reduces the risk of ischemia-related mortality, see clinical trial in De Ferrari et al. (). Thus, heart failure may favorably be treated by the invasive VNS in humans (De Ferrari et al., ) through blunted sympathetic activity and suppressed proinflammatory cytokines, as reviewed in Guiraud et al. (). However, more recent clinical trials in heart failure failed to show efficacy of VNS with respect to reduced rates of death (Gold et al., ). Since stimulation effects of the invasive VNS and aVNS were shown to be similar in reviews of Beekwilder and Beems () and Mercante et al. (b), it can be hypothesized that aVNS could be favorably applied in heart failure, as reviewed in Wang Z. et al. () and He et al. ().

Microcirculation is also potentially subjected to aVNS. Release of vasodilating NO may be involved in mediating cardiovascular responses to aVNS, as mentioned in Sator-Katzenschlager and Michalek-Sauberer (), leading to enhanced peripheral perfusion. NO acts also as a ubiquitous sympatholytic and vagotonic messenger for intracellular signaling in central and peripheral regions of the autonomous control, e.g., the neuronally mediated NO increases NTS neuronal activity and inhibits central sympathetic outflow (Chowdhary and Townend, ). It may be hypothesized that the neuronally mediated NO can be released through the gracile nucleus-thalamic pathway in response to the afferent input and/or input from the dorsal horn neurons (Rong and Ma, ), which were reported to be activated by projections from the great auricular nerve co-stimulated by aVNS (Mahadi et al., ). In addition, since the anti-inflammatory effects of VNS on the vascular level prevented an inflammation-related inhibition of NO release in vascular endothelium (Chapleau et al., ), aVNS with its anti-inflammatory effects may be hypothesized to improve vascular function through endothelial NO release.

Following the modulation of ANS by aVNS, the capillary-venous oxygenation in deep tissues under the skin (at about 8 mm) was observed to increase in diabetic patients, indicating aVNS effects on vasotonus, as indicated by our clinical trial (Kaniusas et al., ). An absolute increase in the mean skin temperature was observed in response to aVNS in single patients with peripheral arterial disease and chronic diabetic wounds, whereas a widening and shrinking of high and low temperature skin regions, respectively, was observed, as shown by a case series in Szeles et al. () and our clinical trial (Clodi, ).

Therefore, aVNS may potentially improve healing of diabetic wounds. Here the potential contributors are an increased local blood perfusion and reduced local inflammation, as indicated by our clinical trial in Kaniusas et al. () and Thomas (), an increased temperature of the wound region, see our clinical trial in Clodi () and a case series in Szeles et al. (), as well as a normalized sympathovagal balance toward parasympathetic predominance due to aVNS, as reviewed in Clayton and Elasy () and shown by our clinical trial (Kampusch et al., b). aVNS in combination with platelet rich fibrin was observed to contribute to avoidance of amputations due to chronic lower leg ulcers resistant to conventional treatment in clinical routine, see a case series in Leitner et al. (). Thus, it may be hypothesized that a multimodal therapeutic concept including aVNS contributes to a better prognosis of patients with diabetic foot syndrome and facilitates a conversion of chronic into active wounds (with their possible closure) avoiding debilitating amputations. Clearly, further studies are certainly needed to reveal underlying mechanisms and prove clinical significance of aVNS in the wound treatment.

Auricular vagus nerve stimulation significantly improved symptoms in peripheral arterial occlusive disease through significantly increased pain-free walking distance, as shown in a case series in Payrits et al. (). However, a clinical trial in Hackl et al. () has shown a significant increase in the initial walking distance in both verum and control groups, whereas the total scope of the Walking Impairment Questionnaire significantly improved only in the verum group.

In patients with the primary Raynaud syndrome, no significant changes in the skin perfusion and temperature were observed in response to aVNS, as shown by a case series in Schlager et al. (); however, aVNS still reduced attack frequency in these patients.

Modulation of Cardioprotective Effects

Ischemic myocardial infarction is resolved by a timely reperfusion of the occluded coronary artery, which results in a robust reduction of the acute mortality but also results in an increased incidence of chronic heart failure. Paradoxically, reperfusion itself causes injury to the tissue, known as myocardial reperfusion injury. In particular, the reperfusion of the jeopardized myocardium is connected with contractile dysfunction, adverse left ventricular remodeling, cell necrosis, and inflammatory response (potentially leading to remote vascular injury). The severity of the myocardial reperfusion injury is tightly related to parasympathetic hypoactivity and sympathetic hyperactivity (Florea and Cohn, ), which is qualitatively in line with the discussed autonomic imbalance in heart failure in humans. Therefore, reestablishment of the sympathovagal balance via the parasympathetic activation &#x; using VNS or aVNS &#x; seems to be a potential therapeutic strategy (Byku and Mann, ).

In a rat model, the invasive VNS reduced the infarct size and ameliorated myocardial dysfunctional vasoconstriction and vasodilatation after myocardial ischemia and reperfusion (Zhao et al., ). These cardio-protective effects of VNS were associated with a marked reduction in inflammatory markers, i.e., pro-inflammatory cytokines (Calvillo et al., ). VNS applied during acute myocardial ischemia markedly reduced arginase expression in the myocardium and aorta (as induced by ischemia and reperfusion), and further elucidated the cardio and vascular protective effect of VNS (Kiss et al., ). In a swine model, VNS reduced infarct size, ventricular fibrillation incidence, and improved cardiac function in the course of strengthened parasympathetic activity (Shinlapawittayatorn et al., ).

Cervical VNS was particularly shown to release NO by neurons (and potentially by myocardial cells) in the heart of rabbits, in addition to the basal NO produced by endothelial cells (Brack et al., ). NO is suggested to enhance the cardiac vagal control while buffering sympathetic activity in terms of VNS-mediated cardioprotection (Chowdhary and Townend, ; Brack et al., ). The released NO may account for a number of VNS effects in the heart, enhancing bradycardia (Chowdhary and Townend, ; Conlon and Kidd, ) and ventricular force control (Brack et al., ). There is evidence that NO mediates the anti-fibrillatory effect of VNS on ventricles (Brack et al., ) and atria (Stavrakis et al., ).

Interestingly, an intermittent but not a continuous VNS attenuated the sympathetic tone and thus reduced the infarct size after myocardial ischemia and reperfusion; in fact, there is a strong association between sympathetic stress and infarct size (Buchholz et al., ). In particular, the continuous VNS in rabbits produced bradycardia and thus long times of the diastolic ventricular filling, leading to increased atrial and ventricular volumes, with the consequence that pressures within atria and ventricles increase. Loading conditions increase, ventricular and atrial walls are stretched, which, in turn, activate embedded vagal afferents. This leads to sympathetic compensatory neural reflexes, potentially responsible for the increase of the infarct size (Buchholz et al., ). In contrast, the intermittent VNS was not able &#x; or was not intense enough &#x; to increase these loading conditions but antagonized intermittently the sympathetic system, reducing the infarct size; compare with the aforementioned effects of strong VNS versus moderate VNS to cease atrial fibrillation.

In analogy with VNS, aVNS was shown to reverse cardiac remodeling, improve cardiac function, and reduce infarct size in dogs with myocardial infarction (Wang et al., a, b). In particular, left atrial and left ventricular dilatation were reduced, left ventricular end-systolic and end-diastolic dimensions were reduced, left ventricular contractile and diastolic functions improved, ejection fraction improved, and interstitial fibrosis and collagen degradation attenuated. Authors in Yu et al. () showed that aVNS was able to reverse atrial remodeling in dogs, increase the effective refractory period in atria, and thus to inhibit inducibility of atrial fibrillation.

Modulation of Psychometric Functions

Auricular vagus nerve stimulation was shown to improve different psychometric functions &#x; as illustrated by the following clinical trials &#x; including well-being, alertness, cognitive performance while decreasing negative mood (Kothe, ), in line with improvement of well-being in Kraus et al. (). Subjective well-being in terms of reduced nausea and tiredness was improved by aVNS during and after oocyte aspiration (Sator-Katzenschlager et al., ). Well-being, activity, and sleep were improved in patients with chronic cervical pain (Sator-Katzenschlager et al., ) and with low back pain (Sator-Katzenschlager et al., ). Anxiety was reduced in chronic pelvic pain patients (Napadow et al., ). A case series in Szeles et al. () reported aVNS to improve the general personal and constitutional condition after abdominal and accident surgery. Preliminary data suggest that aVNS positively affects sleep, as shown by a clinical trial in Becker () and a case series in Szeles et al. (). aVNS may also attenuate postoperative cognitive dysfunction in elderly patients, as hypothesized in Xiong et al. ().

The results of the following clinical trials show that the transcutaneous aVNS seems to improve associative memory performance in older individuals, even after a single treatment session (Jacobs et al., ). aVNS enhanced divergent thinking due to a speculated increase in GABA levels in the brain (Colzato et al., ) and enhanced response selection during action cascading processes indicating the important role of the increased GABA and norepinephrine concentrations (Steenbergen et al., ). Relaxing and sedating effects of aVNS were shown in Litscher et al. () based on a reduced EEG-bispectral index. These positive psychometric effects of aVNS may be potentially ascribed to improved control by ANS and to accelerated parasympathetic activity.

Modulation of Other Functions

Vagus nerve stimulation effects on respiration and gastrointestinal control have been demonstrated (Ness et al., ). For instance, aVNS was shown to strengthen respiratory sinus arrhythmia &#x; i.e., the respiratory-induced and vagus-mediated change in the cardiac interval divided by the tidal volume (La Marca et al., ) &#x; which is proportionally related to the parasympathetic activity.

The rationale for gastrointestinal control by VNS or aVNS is that the vagovagal neurocircuitry modulates the enteric nervous system and thus influences gastric functions (Bonaz and Pellissier, ). For instance, VNS in rats accelerated gastric emptying, caused a greater relaxation or dilation of the pyloric sphincter, and increased antral contraction amplitude, peristaltic velocity but not its contraction frequency (Lu et al., ). Gastric contraction in rats resulted also in response to aVNS (Gao et al., ). aVNS ameliorated burn-induced gastric dysmotility and improved its emptying in rats (Li et al., a). Interestingly, cardiovascular and gastric responses were abolished by blockade of vagal transmission using the muscarinic receptor blocker atropine, which highlights the involvement of VN in both responses and in aVNS (Gao et al., ).

Auricular vagus nerve stimulation was highly efficient in treating a single case of refractory dystonia, whereas preliminary data suggest both an immediate effect of aVNS on motor control loops and even sustainable long-term effects on ANS, see a case study in Kampusch et al. (a). aVNS improved spinal mobility in pain affected patients, see a case series in Kletzl (). aVNS reduced tinnitus severity when paired with tailored sound therapy (Lehtimaki et al., ) and reduced sympathetic dominance in tinnitus patients (Ylikoski et al., ), both are case series. Here neuroplastic effects of aVNS resolving pathological plasticity in the cortex are potentially involved, as reviewed in Clancy et al. (). aVNS was shown to reduce delivery time besides reduced labor pain, as shown in a case series in Grünberger et al. (). aVNS could also be beneficial to treat chronic hiccups in response to an altered VN activity, whereas VN is involved in the afferent and efferent limbs of the hiccup reflex, as reviewed in Clancy et al. (). Likewise, balancing of VN activity via aVNS could also be beneficial in some conditions like chronic cough in order to reduce over-activation of vagal respiratory afferents (Clancy et al., ).

Limitations

A few indirect but rather seldom unwanted effects can also be triggered by aVNS due to afferent-efferent vagal reflexes, with NTS as a potential intermediate stage. The Arnolds ear-cough reflex is the most dominant reflex, in which mechanical irritation of the auricular skin with embedded aVN may cause cough. Other reflexes are ear-gag reflex, ear-lacrimation reflex, ear-syncope reflex, and vaso-vagal reflex. These vegetative reflexes can occur with the respective incidence up to a few percent in the general population (Tekdemir et al., ; Ellrich, ; Napadow et al., ).

In the transcutaneous aVNS, relatively large surface electrodes yield diffuse stimulation fields. Therefore, not only aVN but also other non-vagal fibers in the ear can be expected to be stimulated (Figure 1A). Relatively strong currents and good electrode contacts are required for the current stimuli to circumvent the skin barrier of the ear and still stay suprathreshold in regions innervated by aVN; however, the transcutaneous aVNS is considered as safe (Badran et al., b). The remaining side effects are mostly minor &#x; as related to invasive VNS (Liporace et al., ) &#x; and may include headache, pain and skin irritation at the stimulation site, and dizziness (Mertens et al., ). In contrast to the transcutaneous aVNS, the auricular needle electrodes in the percutaneous aVNS and the resulting focused stimulation favor precise and local stimulation of aVN endings. Here the electrode contact impedance is lower and more reproducible, favoring a low current stimulation. Minor side effects are local skin irritation, local bleeding, local pain, and dizziness. The clinical incidence of skin irritation and inadvertent bleeding can be reduced down to only % using a transillumination technique of the ear (Kaniusas et al., ), which visualizes auricular vessels to avoid random placement of needles (Roberts et al., ).

A special recognition is required on the recent controversy on whether the stimulation effects of aVNS are due to the recruitment of aVN and on the true anatomical location of aVN. The literature on the definite innervation of the auricle is very sparse and is usually based on often cited findings in Peuker and Filler (), which unfortunately show some inconsistencies with respect to aVN innervation regions (Burger and Verkuil, ). These uncertainties impede a proper interpretation of stimulation effects while an optimal target for aVNS is still under debate (Badran et al., a; Burger and Verkuil, ).

Auricular vagus nerve stimulation is typically performed at the tragus or (cavum, cymba) concha (Yakunina et al., ). However, some approaches cover larger areas of the auricle (Sator-Katzenschlager and Michalek-Sauberer, ) with the potential to stimulate concomitantly a few more auricular nerves in addition to aVN, especially the great auricular nerve (with connections to the spinal cord) or the auriculotemporal nerve (connecting to the nucleus spinalis of the trigeminal nerve). Due to a possible co-activation of the great auricular nerve, it may make sense to study in future the activation of spinal cord sites, e.g., dorsal horn activity (Deuchars et al., ). However, current imaging studies in humans are usually focused on VN-activated brain stem nuclei and their projections (Yakunina et al., ). In rats, as reported recently in Mahadi et al. (), tracing of the transcutaneous stimulation at the tragus labeled the dorsal horn of the cervical spinal cord. Here, a central sympathoinhibition by up to 36% was observed in response to the stimulation, as mediated at least in part through sensory afferent projections to the spinal cord and despite of only sparse labeling of NTS, the termination site of aVN (Figure 1A). Authors in Mahadi et al. () also suggest that the tragus stimulation can indirectly influence brainstem regions involved in the sympathetic control via the spinal cord and even suggest an indirect innervation of NTS by recruited aVN via the spinal cord.

It is questioned if the tragus includes aVN endings or only non-vagal endings, such as the great auricular nerve and the auriculotemporal nerve (Badran et al., a; Burger and Verkuil, ). A potential recruitment of these nerves would suggest that mechanisms may be involved for tragal stimulation beyond those anticipated for the sole aVN stimulation. Only the cymba concha was found so far to be solely innervated by aVN (Peuker and Filler, ) with the associated maximum activation of vagal projections in NTS during stimulation, as compared to tragus, cavum concha, or earlobe stimulation (Yakunina et al., ). However, the cymba concha offers some disadvantages in terms of complexity of electrical stimulation by requiring to insert and/or hold an electrode against the concha, as opposed to having to clip onto the tragus.

Lastly, laterality of aVNS is debated. The stimulation of the left or right aVN cannot be expected to yield different physiological effects since afferent information from both sides are centrally merged in the brainstem (Chen et al., b), and the right and left aVN show comparable counts of Aβ fibers (Safi et al., ). This is in clear contrast to the invasive cervical VNS with dominant lateral effects, in which, for instance, the right side stimulation recruits predominantly the sinoatrial node (e.g., with the associated bradycardia) and the left side the atrioventricular node. However, simultaneous activation of the left and right aVN may potentially boost stimulation effects due to increased sensory input to the brainstem.

Future Directions

Even though clinical effects of aVNS and functional projections of aVN are quite consistent, anatomical projections of auricular nerves still lack clarity (Burger and Verkuil, ). This complicates identification of biophysical mechanisms, especially in cardiovascular responses (Mahadi et al., ) as well as in nociception, and thus warrants further anatomical or chemical tracing studies.

The experimental and clinical efficiency of different stimulation patterns needs to be investigated, not only on the local auricular level &#x; as accessible with neuronal models &#x; but also on the systemic body level. The relevance of such investigations is indirectly requested by observations that a strong VNS tends to facilitate atrial fibrillation, whereas a moderate VNS tends to inhibit it (Chen et al., a). Likewise, the intermittent VNS attenuated the sympathetic tone but not the continuous VNS (Buchholz et al., ), whereas hemodynamic changes were observed only at relatively high VNS intensities (Ness et al., ).

Reported data on VNS and aVNS should be interpreted in light of different stimulation methods used in VNS and aVNS and even different methods within aVNS itself (Kaniusas et al., ). In fact, aVNS can be operated as the percutaneous stimulation with a quite focused recruitment of local auricular nerves or as the transcutaneous stimulation with a rather diffuse stimulation and thus a potential recruitment of aVN and non-vagal endings. However, it is important to recognize that whether aVN is stimulated, either itself or with/without other auricular nerves, is potentially less important than recognizing that the clinical effects in humans are real. Here Figure 3 illustrates clinical applications and the relevance of the associated scientific reports that substantiates the authenticity of aVNS effects. It should be noted that the used selection of publications is potentially biased since the present review is a descriptive but not a systematic review.

The prediction of responsiveness to aVNS (or VNS) needs further investigations with respect to baseline conditions of patients as well as their gender and age. For instance, baseline conditions in HRV parameters have shown different influence in VNS and aVNS (Clancy et al., ; Liu et al., ), which potentially indicates different mechanisms of action behind VNS and aVNS. Even in aVNS alone, HRV studies delivered diverging results (De Couck et al., ; Antonino et al., ).

Further basic research in animals and humans is clearly warranted in order to identify and understand reproducible aVNS biologic effects on the single organ and at the systemic level. The transition of animal aVNS models to humans is hardly addressed and should be investigated. The clinical potential of aVNS in treating different medical conditions should be clarified based on solid and prospective clinical studies in humans, whereas aVNS is typically applied for multimodal disease management. For instance, aVNS effects are rather consistent in chronic but not acute pain (Sator-Katzenschlager and Michalek-Sauberer, ). Sustainable physiological effects of aVNS in humans should be quantified.

The paired delivery of VNS and rehabilitative training &#x; known as Paired Vagus Stimulation &#x; indicates improved task-specific plasticity in the brain, providing a more effective rehabilitation. The paired approach was tested in stroke (Dawson et al., ), tinnitus (De Ridder et al., ), post-traumatic stress disorders (Peña et al., ), and other diseases (Hays, ). This may indicate potential advantages of aVNS pairing with rehabilitative stimuli that call for future research in this area.

Conclusion

Auricular vagus nerve stimulation modulates parasympathetic activity of the body inhibiting detrimental sympatho-dominant processes, improves peripheral perfusion due to decreased sympathetic activity, and reduces over-inflammation. Arguable, aVNS has likely a great potential to treat numerous diseases linked with ANS. aVNS may eventually serve as an alternative to reduce opioid use in chronic disease, potentially helping to fight the opioid crisis. Most clinical effects sustain the end of aVNS application, indicating the presence of long-lasting aVNS effects due to inert processes such as the release of neurotransmitters and endorphins, long-term brain plasticity, and self-sustaining changes in the sympathovagal balance.

Auricular vagus nerve stimulation is not close to prime time but gains momentum as a new way of treatment by harnessing the body&#x;s own protective mechanisms beyond the mediation of symptoms, warranting further scientific and clinical research on aVNS. aVNS makes possible to modulate the mind&#x;s great influence over the body via the vagus nerve. An exciting new therapeutic era may begin allowing clinicians to use both electroceuticals and pharmaceuticals in a complementary way for the clear benefit of patients.

Author Contributions

EK, SK, MT, and JS contributed conception and design of the review. EK wrote the first draft of the manuscript. EK and SK performed the initial literature review. FP and MP contributed to anatomical sections of the manuscript. MT, RG, WK, and GV contributed to biological sections of the manuscript. SK and SL contributed to regulatory section of the manuscript. AC, ET, AMS, TT, and WJ contributed to numerical section of the manuscript. VM and AL contributed to sections on personalized stimulation. NI and AS contributed to engineering sections of the manuscript. AK and BP contributed to clinical sections of the manuscript. All authors contributed to manuscript revision, read and approved the submitted version.

Conflict of Interest Statement

EK and SL were employed, and SK is employed by company SzeleSTIM GmbH. JS receives honoraria from SzeleSTIM GmbH and owns patents in the field of the auricular vagus nerve stimulation. EK, SK, and JS are shareholders of SzeleSTIM GmbH.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgments

The authors would like to acknowledge the networking support from the COST (European Cooperation in Science and Technology) Action EMF-MED, the support by the Austrian Research Promotion Agency, and the TU Wien University Library for financial support through its Open Access Funding Program.

References

Afanasiev, S. A., Pavliukova, E. N., Kuzmichkina, M. A., Rebrova, T. Y., Anfinogenova, Y., Likhomanov, K. S., et al. (). Nonpharmacological correction of hypersympatheticotonia in patients with chronic coronary insufficiency and severe left ventricular dysfunction. Ann. Noninvasive Electrocardiol. 21, &#x; doi: /anec

PubMed Abstract | CrossRef Full Text | Google Scholar

Alvord, L. S., and Farmer, B. L. (). Anatomy and orientation of the human external ear. J. Am. Acad. Audiol. 8, &#x;

Google Scholar

Annoni, E. M., Xie, X., Lee, S. W., Libbus, I., KenKnight, B. H., Osborn, J. W., et al. (). Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology. Physiol. Rep. 3:e doi: /phy

PubMed Abstract | CrossRef Full Text | Google Scholar

Antonino, D., Teixeira, A. L., Maia-Lopes, P. M., Souza, M. C., Sabino-Carvalho, J. L., Murray, A. R., et al. (). Non-invasive vagus nerve stimulation acutely improves spontaneous cardiac baroreflex sensitivity in healthy young men: a randomized placebo-controlled trial. Brain Stimul. 10, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Ay, I., Napadow, V., and Ay, H. (). Electrical stimulation of the vagus nerve dermatome in the external ear is protective in rat cerebral ischemia. Brain Stimul. 8, 7&#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Babygirija, R., Sood, M., Kannampalli, P., Sengupta, J. N., and Miranda, A. (). Percutaneous electrical nerve field stimulation modulates central pain pathways and attenuates post-inflammatory visceral and somatic hyperalgesia in rats. Neuroscience , 11&#x; doi: /j.neuroscience

PubMed Abstract | CrossRef Full Text | Google Scholar

Badran, B. W., Brown, J. C., Dowdle, L. T., Mithoefer, O. J., LaBate, N. T., Coatsworth, J., et al. (a). Tragus or cymba conchae? Investigating the anatomical foundation of transcutaneous auricular vagus nerve stimulation (taVNS). Brain Stimul. 11, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Badran, B. W., Mithoefer, O. J., Summer, C. E., LaBate, N. T., Glusman, C. E., Badran, A. W., et al. (b). Short trains of transcutaneous auricular vagus nerve stimulation (taVNS) have parameter-specific effects on heart rate. Brain Stimul. 11, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Badran, B. W., Dowdle, L. T., Mithoefer, O. J., LaBate, N. T., Coatsworth, J., Brown, J. C., et al. (). Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation (taVNS) via electrical stimulation of the tragus: a concurrent taVNS/fMRI study and review. Brain Stimul. 11, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Banni, S., Carta, G., Murru, E., Cordeddu, L., Giordano, E., Marrosu, F., et al. (). Vagus nerve stimulation reduces body weight and fat mass in rats. PLoS One 7:e doi: /journal.pone

PubMed Abstract | CrossRef Full Text | Google Scholar

Barella, L. F., Miranda, R. A., Franco, C. C. S., Alves, S., Malta, A., Ribeiro, T. A. S., et al. (). Vagus nerve contributes to metabolic syndrome in high-fat diet-fed young and adult rats. Exp. Physiol. , 57&#x; doi: /expphysiol

PubMed Abstract | CrossRef Full Text | Google Scholar

Bauer, S., Baier, H., Baumgartner, C., Bohlmann, K., Fauser, S., Graf, W., et al. (). Transcutaneous vagus nerve stimulation (tVNS) for treatment of drug-resistant epilepsy: a randomized, double-blind clinical trial (cMPsE02). Brain Stimul. 9, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Becker, M. (). Electroacupuncture and Autogenic Training for the therapy of Rheumatoid Arthritis: Randomised and Controlled Study. Doctoral dissertation, Medizinische Hochschule Hannover, Hanover.

Google Scholar

Beekwilder, J. P., and Beems, T. (). Overview of the clinical applications of vagus nerve stimulation. J. Clin. Neurophysiol. 27, &#x; doi: /WNP.0bed64d8a

PubMed Abstract | CrossRef Full Text | Google Scholar

Bermejo, P., Lopez, M., Larraya, I., Chamorro, J., Cobo, J. L., Ordonez, S., et al. (). Innervation of the human cavum conchae and auditory canal: anatomical basis for transcutaneous auricular nerve stimulation. Biomed Res. Int. doi: //

PubMed Abstract | CrossRef Full Text | Google Scholar

Bilgutay, A. M., Bilgutay, I. M., Merkel, F. K., and Lillehei, C. W. (). Vagal tuning. A new concept in the treatment of supraventricular arrhythmias, angina pectoris, and heart failure. J. Thorac. Cardiovasc. Surg. 56, 71&#x;

Google Scholar

Billman, G. E., Huikuri, H. V., Sacha, J., and Trimmel, K. (). An introduction to heart rate variability: methodological considerations and clinical applications. Front. Physiol. doi: /fphys

CrossRef Full Text | Google Scholar

Bohotin, C., Scholsem, M., Bohotin, V., Franzen, R., and Schoenen, J. (). Vagus nerve stimulation attenuates heat- and formalin-induced pain in rats. Neurosci. Lett. , 79&#x; doi: /s(03)x

PubMed Abstract | CrossRef Full Text | Google Scholar

Bonaz, B., and Pellissier, S. (). Anti-inflammatory properties of the vagus nerve: potential therapeutic implications of vagus nerve stimulation. J. Physiol. , &#x; doi: /JP

PubMed Abstract | CrossRef Full Text | Google Scholar

Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., et al. (). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature , &#x; doi: /

PubMed Abstract | CrossRef Full Text | Google Scholar

Boscan, P., Pickering, A. E., and Paton, J. F. (). The nucleus of the solitary tract: an integrating station for nociceptive and cardiorespiratory afferents. Exp. Physiol. 87, &#x; doi: /eph

PubMed Abstract | CrossRef Full Text | Google Scholar

Brack, K. E., Patel, V. H., Coote, J. H., and Ng, G. A. (). Nitric oxide mediates the vagal protective effect on ventricular fibrillation via effects on action potential duration restitution in the rabbit heart. J. Physiol. , &#x; doi: /jphysiol

PubMed Abstract | CrossRef Full Text | Google Scholar

Brack, K. E., Patel, V. H., Mantravardi, R., Coote, J. H., and Ng, G. A. (). Direct evidence of nitric oxide release from neuronal nitric oxide synthase activation in the left ventricle as a result of cervical vagus nerve stimulation. J. Physiol. , &#x; doi: /jphysiol

PubMed Abstract | CrossRef Full Text | Google Scholar

Browning, K. N. (). Glucose and the vagus: sensory cells savour sweet substances. J. Physiol. , &#x; doi: /jphysiol

CrossRef Full Text | Google Scholar

Buchholz, B., Donato, M., Perez, V., Deutsch, A. C. R., Hocht, C., Del Mauro, J. S., et al. (). Changes in the loading conditions induced by vagal stimulation modify the myocardial infarct size through sympathetic-parasympathetic interactions. Pflugers Arch. , &#x; doi: /s

PubMed Abstract | CrossRef Full Text | Google Scholar

Burger, A. M., and Verkuil, B. (). Transcutaneous nerve stimulation via the tragus: are we really stimulating the vagus nerve? Brain Stimul. 11, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Busch, V., Zeman, F., Heckel, A., Menne, F., Ellrich, J., and Eichhammer, P. (). The effect of transcutaneous vagus nerve stimulation on pain perception&#x;an experimental study. Brain Stimul. 6, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Calvillo, L., Vanoli, E., Andreoli, E., Besana, A., Omodeo, E., Gnecchi, M., et al. (). Vagal stimulation, through its nicotinic action, limits infarct size and the inflammatory response to myocardial ischemia and reperfusion. J. Cardiovasc. Pharmacol. 58, &#x; doi: /FJC.0beb

PubMed Abstract | CrossRef Full Text | Google Scholar

Capone, F., Assenza, G., Di Pino, G., Musumeci, G., Ranieri, F., Florio, L., et al. (). The effect of transcutaneous vagus nerve stimulation on cortical excitability. J. Neural Transm. , &#x; doi: /s

PubMed Abstract | CrossRef Full Text | Google Scholar

Capone, F., Miccinilli, S., Pellegrino, G., Zollo, L., Simonetti, D., Bressi, F., et al. (). Transcutaneous vagus nerve stimulation combined with robotic rehabilitation improves upper limb function after stroke. Neural Plast. doi: //

PubMed Abstract | CrossRef Full Text | Google Scholar

Chae, J.-H., Nahas, Z., Lomarev, M., Denslow, S., Lorberbaum, J. P., Bohning, D. E., et al. (). A review of functional neuroimaging studies of vagus nerve stimulation (VNS). J. Psychiatr. Res. 37, &#x; doi: /s(03)

CrossRef Full Text | Google Scholar

Chakravarthy, K., Chaudhry, H., Williams, K., and Christo, P. J. (). Review of the uses of vagal nerve stimulation in chronic pain management. Curr. Pain Headache Rep. doi: /s

PubMed Abstract | CrossRef Full Text | Google Scholar

Chapleau, M. W., Rotella, D. L., Reho, J. J., Rahmouni, K., and Stauss, H. M. (). Chronic vagal nerve stimulation prevents high-salt diet-induced endothelial dysfunction and aortic stiffening in stroke-prone spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol. , H&#x;H doi: /ajpheart

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, M., Yu, L., Liu, Q., Jiang, H., and Zhou, S. (a). Vagus nerve stimulation: a spear role or a shield role in atrial fibrillation? Int. J. Cardiol. , &#x; doi: /j.ijcard

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, M., Yu, L., Ouyang, F., Liu, Q., Wang, Z., Wang, S., et al. (b). The right side or left side of noninvasive transcutaneous vagus nerve stimulation: based on conventional wisdom or scientific evidence? Int. J. Cardiol. , 44&#x; doi: /j.ijcard

PubMed Abstract | CrossRef Full Text | Google Scholar

Chen, S.-P., Ay, I., de Morais, A. L., Qin, T., Zheng, Y., Sadeghian, H., et al. (c). Vagus nerve stimulation inhibits cortical spreading depression. Pain , &#x; doi: /j.pain

PubMed Abstract | CrossRef Full Text | Google Scholar

Cho, H. K., Park, I. J., Jeong, Y. M., Lee, Y. J., and Hwang, S. H. (). Can perioperative acupuncture reduce the pain and vomiting experienced after tonsillectomy? A meta-analysis. Laryngoscope , &#x; doi: /lary

PubMed Abstract | CrossRef Full Text | Google Scholar

Cimpianu, C.-L., Strube, W., Falkai, P., Palm, U., and Hasan, A. (). Vagus nerve stimulation in psychiatry: a systematic review of the available evidence. J. Neural Transm. , &#x; doi: /s

PubMed Abstract | CrossRef Full Text | Google Scholar

Clancy, J. A., Mary, D. A., Witte, K. K., Greenwood, J. P., Deuchars, S. A., and Deuchars, J. (). Non-invasive vagus nerve stimulation in healthy humans reduces sympathetic nerve activity. Brain Stimul. 7, &#x; doi: /j.brs

PubMed Abstract | CrossRef Full Text | Google Scholar

Clark, K. B., Smith, D. C., Hassert, D. L., Browning, R. A., Naritoku, D. K., and Jensen, R. A. (). Posttraining electrical stimulation of vagal afferents with concomitant vagal efferent inactivation enhances memory storage processes in the rat. Neurobiol. Learn. Mem. 70, &#x; doi: /nlme

PubMed Abstract | CrossRef Full Text | Google Scholar

Clayton, W., and Elasy, T. A. (). A review of the pathophysiology, classification, and treatment of foot ulcers in diabetic patients. Clin. Diabetes 27, 52&#x; doi: /diaclin

CrossRef Full Text | Google Scholar

Clodi, C. A. (). Thermographic Changes Due to Percutaneous Electrical Stimulation of Ramus Auricularis Nervi Vagi in Patients with Diabetic Foot Syndrome and Healthy Persons. Diploma thesis, Medical University of Vienna, Vienna.

Google Scholar

Colangelo, A. M., Alberghina, L., and Papa, M. (). Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci. Lett. , 59&#x; doi: /j.neulet

PubMed Abstract | CrossRef Full Text | Google Scholar

Colzato, L. S., Ritter, S. M., and Steenbergen, L. (). Transcutaneous vagus nerve stimulation (tVNS) enhances divergent thinking. Neuropsychologia , 72&#x; doi: /j.neuropsychologia

PubMed Abstract | CrossRef Full Text | Google Scholar

Conlon, K., and Kidd, C. (). Neuronal nitric oxide facilitates vagal chronotropic and dromotropic actions on the heart. J. Auton. Nerv. Syst. 75, &#x; doi: /s(98)

PubMed Abstract | CrossRef Full Text | Google Scholar

Conway, C. R., Sheline, Y. I., Chibnall, J. T., George, M. S., Fletcher, J. W., and Mintun, M. A. (). Cerebral blood flow changes during vagus nerve stimulation for depression. Psychiatry Res. , &#x; doi: /j.pscychresns

PubMed Abstract | CrossRef Full Text | Google Scholar

Conway, C. R., and Xiong, W. (). The mechanism of action of vagus nerve stimulation in treatment-resistant depression. Psychiatr. Clin. North Am. 41, &#x; doi: /j.psc

PubMed Abstract | CrossRef Full Text | Google Scholar

Dawson, J., Pierce, D., Dixit, A., Kimberley, T. J., Robertson, M., Tarver, B., et al. (). Safety, feasibility, and efficacy of vagus nerve stimulation paired with upper-limb rehabilitation after ischemic stroke. Stroke 47, &#x; doi: /STROKEAHA

PubMed Abstract | CrossRef Full Text | Google Scholar

De Couck, M., Cserjesi, R., Caers, R., Zijlstra, W. P., Widjaja, D., Wolf, N., et al. (). Effects of short and prolonged transcutaneous vagus nerve stimulation on heart rate variability in healthy subjects. Auton. Neurosci. , 88&#x; doi: /j.autneu

PubMed Abstract | CrossRef Full Text | Google Scholar

De Couck, M., Mravec, B., and Gidron, Y. (). You may need the vagus nerve to understand pathophysiology and to treat diseases. Clin. Sci. , &#x; doi: /CS

PubMed Abstract | CrossRef Full Text | Google Scholar

Sours: https://www.frontiersin.org/articles//fnins/full

Acupuncture and The Vagus Nerve

Research has linked reduced vagus nerve activity to non-communicable conditions like cardiovascular diseases, cancer and chronic obstructive pulmonary disease.

"Vagal nerve activity is related to frontal brain activity which regulates unhealthy lifestyle behaviors. Epidemiologically, high vagal activity, indexed by greater heart rate variability (HRV), independently predicts reduced risk of GBD (global burden of diseases) and better prognosis in GBD. Biologically, the vagus nerve inhibits oxidative stress, inflammation and sympathetic activity (and associated hypoxia)."

Source: https://www.mdpi.com//7/10//htm

Another study showed that acupuncture can help stimulate the vagus nerve which in turn has anti-inflammatory effects on the body.

“The present study provides evidence that AS (acupuncture stimulation) transmits signals into the vagus nerve and mediates anti-inflammatory responses in the spleen. Using an animal model of acute inflammation, we found that AS attenuated inflammatory responses as measured by TNF-α productions in the serum and the spleen. Removal of vagal and splenic nerves significantly abrogated the anti-inflammatory effects mediated by AS.

Sours: https://www.morningsideacupuncturenyc.com/blog/acupuncture-and-the-vagus-nerve
  1. Tiny christmas cross stitch patterns
  2. Troy bilt horse tiller engine
  3. Free holy communion clip art

The vagus nerve is the epicentre of the mind-body connection. Signals that are carried from the gut and organs via the vagus nerve influence the entire brain. These messages effect the way that you feel and subliminal decisions are made from these signals, that can profoundly influence your actions. 

One of the ways to measure how the vagus nerve is functioning is by assessing your heart rate variability. Heart rate variability refers to the oscillations of your heart rate that occur with the breath.

Higher heart rate variability is associated with a greater ability to recover from difficult situations. On the other hand, lower heart rate variability is associated with prolonged stress, anxiety and emotional disregulation that carries on after a situation that was challenging for us has ended (Laborde et al,  https://www.frontiersin.org/articles//fpsyg/full)

By harnessing the vagus nerve you can improve your heart rate variability and build flexibility and resilience within your autonomic nervous system. 

If you think back to a recent stressful event you might ask yourself: 

• How long did it take for me to return to a state of calm after I was stressed?

• Did the amount of fear/anxiety/stress/anger that came up for me appropriately match this situation?

• Am I often experiencing a sense of fear or worry even though I know things are ok rationally? 

• Do I get gastrointestinal issues after stress? 

• Do I experience insomnia in difficult times?

Emotional health is also a foundation of your physical health. There is a flow on effect of your emotional states to your immune system, digestive system, your heart and lungs, your sleep and your ability to connect with others. Chronic emotional states can actually age you faster! 

Incorporating tools and techniques that balance your nervous system via the vagus nerve will not only improve your long-term digestive health, emotional health and immunity, it also helps you forge richer and more lasting connections with others.

In time and with the right tools it can become easier to move between feelings of fear and anxiety, back to a state of calm and ease. It is possible to get relief from anxiety and depression, gastrointestinal issues, sleep disturbances and chronic pain when you work with your vagus nerve. 

 Acupuncture, transcutaneous vagus nerve stimulation and mind-body neural practices can modulate pro-inflammatory cytokines released by the nervous system under stress, and therefore dampen the inflammatory response. The process of stimulation to the vagus nerve, or improving Vagal Tone, influences the markers of inflammation.

Acupuncture inhibits the synthesis of tumour necrosis factor and evokes the activity of the vagus nerve. The acupuncture points in the sub-occipital, auricular (ear) and neck-region are located in the nerve distribution area and affect the vagus nerve. One of the benefits of using acupuncture to stimulate the vagus nerve is that it is risk- and surgery-free and doesn’t produce any negative side effects.

The vagus nerve is the longest nerve in our body and connects the brain with many important organs, including the intestines, stomach, lungs and heart.  The vagus nerve is also an important part of the parasympathetic ‘rest & digest’ nervous system and is the nerve that influences your breathing, digestive function and heart rate, which all ultimately affect your mental health.

Moreover, you need to pay special attention to the tone of your vagus nerve, which refers to the biological process that encourages and triggers the activity of the vagus nerve. If this vagal tone increases, it will activate the parasympathetic nervous system. This means that having higher vagal tone means you can relax a lot quicker even while under stress. 

Although this vagal tone is also connected to inflammation, immune system, metabolism and emotional regulation, which is essential to our body. This means the vagus nerve has been associated with mental health conditions, such as anxiety. Low vagal tone is related to poor emotional and attentional regulation, inflammation and depression and can also be used to measure your sensitivity to stress.

Vagus Nerve Treatment Through Acupuncture

Acupuncture has been used to treat various diseases for more than years. As the name suggests, acupuncture is a medical intervention that involves applying fine needles to specific parts of the body known as acupuncture points or acupoints.

Acupuncture originated in Asia and, according to those who use it, facilitates the flow of Qi, which is the life force circulating through our body in the form of meridians. Acupoints are presumed to be pathophysiologically associated, which means they reflect the status of visceral organs and systemic conditions. This is why the stimulation of specific acupoints may also evoke a response in the vagus nerve and improve its tone.

Acupuncture stimulation is applied to the acupoint or a closely affected area for muscle treatment. On the other hand, distal acupuncture stimulation is used to target diseases present in internal organs, such as in the vagus nerve. 

Our trained professionals use manual acupuncture that involves penetrating the skin with a metallic needle and manipulating it by rotating in one or both directions or lifting and thrusting.

According to our professionals, patients may feel a sensation that spreads to other parts of the body, which is considered a useful criterion when evaluating the therapeutic efficacy of acupuncture. According to the reports, acupuncture is an effective treatment for many types of diseases through its ability to regulate inflammatory responses.

Vagus Nerve Treatment Through Mind-Body Therapy

Jessica also provides mind-body therapy for disorders affecting the vagus nerve. A healthy vagus nerve is able to comfortably support your digestive system, which helps regulate sleep patterns and settle nerves. Learning to the regulate vagal tone is associated with a reduction in inflammation and more accurate prognosis in people suffering from chronic illness, migraines, auto-immune disorders, vagus nerve anxiety and depression.

Ventral vagal complex, or VVC, is the social communication system in charge of soothing and calming. The social nervous system gets its name because it is responsible for your facial expressivity.

Heart Rate Variability and Vagal Tone

Vagal tone is measured through the oscillations in heart rate that occur when we breathe. This is known as heart rate variability, or HRV. So, the healthy tone of your vagus nerve depends on a slight increase in heart rate when inhaling and a decrease in heart rate when exhaling. 

Here, a healthy vagal tone can be considered an optimal balance of parasympathetic and sympathetic nervous system actions. Generally, people with higher HRV can shift more easily from excitement to relaxation and can recover more quickly from stress.

Tone Your Vagus Nerve

Mind-body therapies are known to regulate the vagus nerve and increase resilience through ‘safe mobilisation and safe immobilisation’. This will initially develop your capacity to feel peaceful, calm and connected. After you have developed a solid foundation for accessing your social nervous system, you can begin slowly building your tolerance for triggering physiological activation.

Further, mind-body therapy from Jessica will simultaneously tend to your bodily sensations, breath, emotional experience and thoughts. In addition, you can focus on sensing your external environment to recognise your safety in the present moment.

Services Jessica Maguire Offers

Jessica Maguire is a physiotherapist who helps patients integrating the modalities of manual therapy with acupuncture and mind-body therapies. Jessica offers her patients a reduction in pain and an increase in wellbeing in the form of better sleep, improved inflammation, enhanced mood and energy levels and a more stable digestive system.

Jessica offers integrative acupuncture involving the examination of tissue and movement dysfunction found in manual therapies along with meridian examination often used in traditional Chinese medicine. She also helps her patients improve their autonomic nervous system and vagal tone to reduce pain, inflammation, stress, vagus nerve anxiety and depression.

Sours: https://www.jessicamaguire.com/vagus-nerve-anxiety-treatment
Vagus nerve: location, branches and function (preview) - Neuroanatomy - Kenhub

Application of Polyvagal Theory to Auricular Acupuncture

References

1. Nogier P. Treatise of Auriculotherapy. Moulins-les Metz, France: Maisonneuve; [Google Scholar]

2. Oleson TD, Kroening RJ, Bresler DE. An experimental evaluation of auricular diagnosis: The somatotopic mapping of musculoskeletal pain at ear acupuncture points. Pain ;8(2)&#x; [PubMed] [Google Scholar]

3. Wexu M. The Ear Gateway to Balancing the Body: A Modern Guide to Ear Acupuncture. New York: ASI Publishers; [Google Scholar]

4. Smith M. Acupuncture and natural healing in drug detoxification. Am J Acupunct. ;&#x; [Google Scholar]

5. Porges SW. The Polyvagal Theory: Neurophysiological Foundations of Emotions, Attachment, Communication, and Self-Regulation. New York: W.W. Norton &#x; Co.; [Google Scholar]

6. Huang L-C. Auricular Medicine, the New Era of Medicine and Healing. Birmingham, Alabama: Auricular Medicine Center; [Google Scholar]

Sours: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC/

Nerve point vagus ear acupuncture

Transcutaneous electrical stimulation at auricular acupoints innervated by auricular branch of vagus nerve pairing tone for tinnitus: study protocol for a randomized controlled clinical trial

  • Study protocol
  • Open Access
  • Published:
  • Tian-Tian Li1,
  • Zhao-Jun Wang1,
  • Song-Bai Yang2,
  • Jun-Hong Zhu2,
  • Shi-Zhong Zhang1,
  • San-Jin Cai1,2,
  • Wen-Han Ma1,
  • Ding-Qi Zhang1 &
  • Zhi-Gang Mei1,2

Trialsvolume 16, Article number:  () Cite this article

  • Accesses

  • 21 Citations

  • 3 Altmetric

  • Metrics details

Abstract

Background

Subjective tinnitus is a phantom sensation experienced in the absence of any source of sound. Its mechanism remains unclear, and no approved drugs are available. Vagus nerve stimulation (VNS) is an exciting new method to treat tinnitus, but direct electrical stimulation of the cervical vagus has disadvantages. This randomized controlled clinical trial aims to overcome these limitations by stimulating the auricular branch of vagus nerve (ABVN) on the outer ear. Since the ABVN is the only peripheral branch of the vagus nerve distributed on the ear’s surface, it should be possible to achieve analogous efficacy to VNS by activating the central vagal pathways. However, researches have indicated that the curative effect lies in a combination of auditory and vagal nerve stimulation. Moreover, from traditional Chinese theory, auricular acupoints used to treat tinnitus are mainly in the regions supplied by the ABVN. Whether stimulation at the auricular acupoints is due to unintentional stimulation of vagal afferent fibers also needs evidence.

Methods/design

A total of subjects with subjective tinnitus are randomized equally into four groups: (1) electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by the ABVN; (2) electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by ABVN pairing tones; (3) electrical stimulation at auricular acupoints innervated by non-ABVN pairing tones; (4) electrical acupuncture. Patients will be treated for 30 minutes every other day for 8 weeks. The primary outcome measure is the Tinnitus Handicap Inventory. The secondary outcome measure combines a visual analogue scale to measure tinnitus disturbance and loudness with the Hospital Anxiety and Depression Scale. Assessment is planned at baseline (before treatment) and in the 4th and 8th week, with further follow-up visits after termination of the treatment at the 12th week. Any adverse events will be promptly documented.

Discussion

Completion of this trial will help to confirm whether ABVN or the combination of ABVN and sound stimulus plays a more important role in treating tinnitus. Moreover, the result of this clinical trial will enhance our understanding of specific auricular acupoints.

Trial registration

Chinese Clinical Trials Register ChiCTR-TRC

Peer Review reports

Background

Subjective tinnitus is considered as a phantom sensation experienced in the absence of any internal or external acoustic stimulus. It can be perceived as a hissing, buzzing, humming, roaring, whistling, or ringing sound in one or both ears, or somewhere in the head. At present, tinnitus has becoming the most common otology problem, affecting 10% to 30% of the general population and an estimated prevalence of % in the older population [1]. Meanwhile, with the growing popularity of electronic music, young people experience transient or permanent tinnitus at a ratio of % and %, respectively, after exposure to loud music [2]. Among severe tinnitus sufferers, tinnitus-related sensations, such as anxiety, annoyance, frustration, and depression lead to a negative impact on quality of life in 70% of those affected [3], and they are usually told that they must learn to live with it. Yet the pathological mechanisms that underlie tinnitus perception remain largely hypothetical and are still not well understood. Currently, the universally accepted hypothesis is that interactions between altered cochlear inputs and distorted central auditory processing provoke tinnitus. Studies have supported that subjective tinnitus may be a result of the expression of neural plasticity and that anomalies may develop because of decreased input from the ear, deprivation and sound stimulation, overstimulation or other factors as yet unknown. For the buried pathological mechanisms, treatment options are limited. No physiotherapy treatments can yet be considered sufficient in providing long-term reduction of tinnitus impact and there is no drug approved by the European Medicines Agency or the Food and Drug Administration on the market [4,5]. Therefore, an effective and safe therapy for tinnitus is of considerable importance to meet this significant unmet clinical need.

Vagus nerve stimulation (VNS) is approved by the Food and Drug Administration for both refractory epilepsy and resistant depression [6,7]. VNS offers an exciting new perspective for the treatment of tinnitus and it has recently been demonstrated that VNS is a promising method [8]. In this method, an electrode surgically implanted around the left cervical vagus nerve is connected to a pulse generator placed subcutaneously in the upper chest. However, considering the disadvantages of the implantation, including lesions of the vagus nerve, infection, shortness of breath, possible mechanical failure of electronic equipment, and battery replacement, a relatively safe and well tolerated improved method is desired. To minimize side effects, stimulation of the auricular branch of vagus nerve (ABVN) has been suggested [9]. The ABVN is the only peripheral branch of the vagus nerve distributed on the surface of ear, and studies using the transganglionic horseradish peroxidase method [10,11] have shown that it mainly projects to the nucleus of the solitary tract in the brainstem. Functional magnetic resonance imaging and vagus sensory evoked potentials revealed that ABVN stimulation shows considerable similarity to implanted VNS, with both acting through the central auditory pathway of the vagus nerve [12,13]. Thus, it would be safer simply to deliver mild electric shocks to the skin of the outer ear instead of resorting to VNS with surgery. However, some researchers reported that ABVN stimulation alone seems to have no relevant improvement of tinnitus complaints [8,14], and it is suggested that the combination with other interventions, such as sound stimuli, which would reduce the cortical response to mid-frequency tones, increase frequency selectivity, and decrease cortical synchronization [15] should be considered. But there is not currently enough evidence in clinical practice of the effect of the method of pairing tones with stimulation at ABVN.

Moreover, auricular acupuncture, the underlying mechanism of which is unclear, has been used to treat tinnitus for thousands of years [16]. Auricular acupoints applied to treat tinnitus such as Kidney (CO10), Yidan (CO11), Liver (CO12) and Shenmen (TF4) are distributed in the regions supplied by ABVN [17]. So whether auricular acupoints are due to an unintentional stimulation of the vagal afferent fibers also needs more clinical and experimental evidence.

Therefore, we have designed a randomized, four-arm, controlled clinical study to provide a conclusive answer. In this trial, our aim is to attempt to confirm whether ABVN or the combination of ABVN and sound stimulus plays a more important role in the treatment of tinnitus. Moreover, the result of this clinical trial will enhance our understanding of specific auricular acupoints.

Methods/design

Design

This is a randomized, single-blind, four-armed, controlled clinical trial conducted in Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University. Study patients will be screened based on specific inclusion and exclusion criteria. Before beginning the treatment, all candidates will undergo a standard neuro-otological examination and a baseline audiometric assessment, including measurement of hearing thresholds, minimal masking levels, loudness discomfort levels, and stapedial reflexes, performed by professional audiologists. Then they will be equally randomized into four groups: (1) electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by ABVN (the ABVN group); (2) electrical stimulation at auricular acupoints (CO10, CO11, CO12, and TF4) innervated by ABVN pairing tones (the ABVN plus tone group); (3) electrical stimulation at auricular acupoints innervated by non-ABVN pairing tones (the non-ABVN plus tone group); (4) an electrical acupuncture group. Detailed information regarding the clinical procedures is presented in Figure 1. The clinical endpoints are assessed by blinded independent statisticians. Any adverse effects during the course will be reported. This trial was registered on the Chinese Clinical Trial Register (ChiCTR-TRC).

Flow chart. ABVN, auricular branch of vagus nerve; HADS, Hospital Anxiety and Depression Scale; THI, Tinnitus Handicap Inventory; VAS, visual analogue scale.

Full size image

The trial will be performed according to the principles of the Declaration of Helsinki (Edinburgh version, ). In addition, written informed consent will be obtained from all participants. Ethical permission was obtained from the Research Ethical Committee of Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University. The ethics committee approval number is

Recruitment period and methods

Patients will be enrolled in Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University with a target sample size of subjects. We will recruit the participants by advertising in the hospitals, in public newspapers and on the internet homepages of hospitals. The trial will be executed from July to July

Types of participant

Inclusion criteria

Qualified participants meeting all of the following conditions will be recruited [18,19]:

  1. 1.

    Single-tone subjective tinnitus, typical conditions of unilateral or bilateral;

  2. 2.

    Age 15 to 65 years, either sex;

  3. 3.

    Recurrent attacks for more than 1 month or persist attacks for more than 5 days;

  4. 4.

    Must be able to hear stimulation tones presented by the device at all frequencies;

  5. 5.

    Must be able to complete the forms and use the rating scales;

  6. 6.

    Not be taking part in any other clinical trial during the period;

  7. 7.

    Voluntarily signed informed consent forms.

Exclusion criteria

Participants who experience or have one or more of the following conditions will be excluded:

  1. 1.

    Objective tinnitus or Ménière’s disease;

  2. 2.

    Tinnitus induced by otitis media, otitis interna or cerebellopontine angle tumors;

  3. 3.

    Postcochlear lesion;

  4. 4.

    Patients with severe diabetes, hypertension or cardiovascular disease, or mental disease;

  5. 5.

    Patients unable to read, understand and complete the forms or use the rating scales;

  6. 6.

    Pregnant or preparing for pregnancy.

Randomization and blinding

One researcher screens and enrolls participants at the clinic. Patients are numbered according to registration order. After participants have completed a baseline evaluation, another researcher who is uninvolved with data collection randomly assigns them to one of four treatment groups in a ratio using a computer-generated, blocked randomization sequence generated using SPSS software (SPSS Inc., Chicago, IL, USA). This researcher informs the therapist of the treatment assignment.

We applied a single-blind design in which the study patients, data collocation staff, and data analysts are blinded during the study protocol. The therapists are not blinded to the treatments they deliver because treatment manipulation makes it impossible. During the intervention, therapists and data collection staff are instructed not to exchange information with each other nor communicate with the study patients.

Interventions

Specific interventions of each group are as follows (Figure 2).

Locations and stimulation devices. (A) Points used in the ABVN group and the ABVN plus tone group for transcutaneous electrical nerve stimulation. (B) Points used in the non-ABVN plus tone group for transcutaneous electrical nerve stimulation. (C) Acupoints used in the electrical acupuncture group. (D) Locations of acupoints in the acupuncture group. local acupoints: Tinghui (GB2) and Yifeng (TF17); distal acupoints: Zhongzhu (TE3) and Xiaxi (GB43). (E) Innervation of the human auricle, including ABVN (blue grid), great auricular nerve (green grid) and auriculotemporal nerve (red grid) [17]; the black areas show the specific auricular acupoints. TF4, CO, and HX1 are used in the ABVN group and the ABVN plus tone group; HX9 and LO5 are used in the non-ABVN plus tone group. (F) Ideograph of sound (tones) stimulus: each speakers is equidistant from the head of the subject.

Full size image

ABVN group

All participants will receive transcutaneous electrical stimulation at auricular acupoints innervated by the ABVN. The points are located at the cymba conchae and the triangular fossa, where there is rich ABVN distribution [17]. Main stimulation points according to standard practice include Kidney (CO10), Yidan (CO11), Liver (CO12), and Shenmen (TF4). A transcutaneous electrical nerve stimulator (Suzhou Medical Appliance Co. Ltd., Suzhou, China) will be used in this group. Two carbon-impregnated silicone electrode tips are connected to the transcutaneous electrical nerve stimulator by metal wire; one tip contacts the skin surface points and the other acts as a terminal end in the ear. The stimulation frequency is 20 Hz, the stimulation current is 1 to 5 mA, with stimulus pulses shorter than 1 ms in duration. Each session will last 30 minutes; sessions are performed every other day for 8 weeks.

ABVN plus tone group

The format will be exactly the same as for the ABVN group. Multiple tones will be delivered by Tinnitus Measurer software (Neonix, USA) at a comfortable listening level during the transcutaneous electrical nerve stimulation. Randomly interleaved pure tones that span the hearing range but exclude the tinnitus tone will be selected. Each session will last 30 minutes; sessions are performed every other day for 8 weeks.

Non-ABVN plus tone group

The format of this group will be the same as for the ABVN plus tone group, except that the subjects receiving stimulation will be stimulated at auricular acupoints supplied by the great auricular nerve [17]. Each session will last 30 minutes; sessions are performed every other day for 8 weeks.

Electrical acupuncture group

The subjects of this group will be treated with electrical acupuncture at local and distal points. Acupuncture points are selected as follows. 1. local acupoints: Yifeng (TE17), Tinghui (GB2); 2. distal acupoints: Xiaxi (GB43), Zhongzhu (TE3). Patients will be in a comfortable and relaxed position and asked to concentrate on the treatment task. After the needles are inserted into the acupoints, they will be connected to an electrical point stimulation device (GA, Shanghai Huayi Medical Instrument CO., Ltd, Shanghai, China) operating at a frequency of 20 Hz and current of 1 to 5 mA, with pulses shorter than 1 ms in duration. The intensity will be adjusted individually based on the tolerance of the patient. All parameters of the electrical stimulation inducing twitching of the muscles indicate effective stimulus. After retaining the needles for 30 min, all needles are taken out using alcohol-soaked cotton balls to avoid infection and bleeding.

The needles (Suzhou Medical Supplies Factory Co., Ltd. Suzhou, China) used in this group are 25 mm in length and  mm in diameter. Electrical acupuncture is performed by a therapist with rich clinical experience and acupuncture licenses for Chinese medicine practitioners from the Ministry of Health of China. Treatment will be conducted over a period of 8 weeks, at a frequency of every other day.

Primary outcome measures

The primary outcome is evaluated using the Tinnitus Handicap Inventory, which evaluates 25 items grouped into a functional subscale (11 factors), an emotional subscale (9 factors), and a catastrophic subscale (5 factors). Each question of the Tinnitus Handicap Inventory can be answered by either ‘often’ (4 points), ‘sometimes’ (2 points), or ‘never’ (0 points). The total score allows the tinnitus to be categorized as: ‘slight’ (0 to 16 points), ‘mild’ (18 to 36 points), ‘moderate’ (38 to 56 points), ‘severe’ (58 to 76 points), or ‘catastrophic’ (78 to points). The assessment is at baseline (before randomization), and in the 4th and 8th week, with further follow-up visits after termination of the treatment at the 12th week.

Secondary outcome measures

A visual analogue scale, measuring the disturbance and the loudness of the tinnitus will be used. This consists of  mm lines with ‘0 = total absence’ and ‘ = maximum’ of tinnitus disturbance and loudness, respectively.

The severity of both anxiety and depression is evaluated using the Hospital Anxiety and Depression Scale, in which seven items for anxiety and another seven items for depression are assessed. Each item is answered by the patients on a four point (0 to 3) response category. A score of 0 to 7 for either subscale could be regarded as being in the normal range, a score of 8 to 10 is just suggestive of the presence of the respective state and a score of 11 or higher indicates the probable presence of the mood disorder [20]. Both of these assessments will be used at baseline (before randomization), and in the 4th and 8th week, with further follow-up visits after termination of the treatment at the 12th week.

Statistical methods

The trial aims to detect a difference between the four study groups. We present here our power analysis for the primary outcome only. This is deemed a clinically significant difference of a point or greater reduction in score on the Tinnitus Handicap Inventory following treatments. Since this is a novel therapy, we used data from a previous proof-of-concept feasibility study [21], the mean decrease rate is 28% in the VNS group and % in the control group.

The following formula was used for a four-group trial [22]:

$$ {n}_1={n}_2=\frac{{\left({\mu}_{\alpha }+{\mu}_{\beta}\right)}^22P\left(1-P\right)}{{\left({P}_1-{P}_2\right)}^2} $$

Calculations are performed using 80% power and a 5% significance level (two-side). The required sample size is approximately 27 participants for each group. Assuming a 10% dropout rate, we plan to enroll a total of participants with four groups of equal size (30 participants per group).

Statistical analysis

In this trial, our primary outcome measure is the Tinnitus Handicap Inventory. We define the treatment response as a reduction in score on the Tinnitus Handicap Inventory following treatments of 20 points or more. First, baseline characteristics will be analyzed using descriptive statistics for each group. Then repeated measures analysis is performed to make comparisons among the treatment groups and the control group (ABVN plus tone versus electrical acupuncture, non-ABVN plus tone versus electrical acupuncture, and ABVN versus electrical acupuncture) at different time points (4th, 8th, and 12th week). If a significant difference is found, the next step is to make comparisons among the three treatment groups in effectiveness. Multiple comparisons will be adjusted according to the Bonferroni correction method. The Kruskal-Wallis test will be employed in the analysis of skewed distribution data. Analysis of variance will be used for numerical variables, and the χ2 test for categorical variables.

Statistical analysis will be performed by the Medical College of China Three Gorges University, No.8, University Avenue, Yichang, Hubei, China. The statistician is blinded from the allocation of groups. The SPSS software package (SPSS Inc., Chicago, IL, USA) will be used to analyze the data.

Participant protections and ethics

The protocol adheres to the latest revision of the Helsinki Declaration and the Chinese law of human study and has been approved by the Research Ethical Committee of Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University. The participants are informed of the potential benefits, risks, alternatives, and responsibilities during the study before they are asked to provide consent. Potential mild adverse events, reported to be related to electro-acupuncture treatment, are pain, bleeding, tiredness, and a feeling of faintness in the acupuncture group [23], and skin redness and pressure marks in the other groups, but these mild symptoms will generally resolve spontaneously after treatment. Additionally, ABVN is thought to be involved in some peculiar somatovisceral reflexes. For instance, an ear-cough reflex (Arnold’s reflex) is estimated to be present in approximately 4% [24] of the general population, while there is rare occurrence of ear-gag reflex, ear-lacrimal reflex and auricular syncope [24,25]. So there is a rare possibility that patients in the two groups receiving ABVN stimulation might have these reflexes. Participants who show any adverse effects during the course of the therapy will receive appropriate treatment immediately. All adverse effects will be documented, and patients with persistent worsening symptoms will be withdrawn from the study.

Discussion

We have presented the design and protocol for the randomized controlled clinical study for tinnitus patients. If it proves successful, this new treatment method could offer hope to millions of patients who are affected by tinnitus.

Although the exact pathophysiology of tinnitus still remains elusive, it is believed that an abnormal balance between inhibition and excitation causing map reorganization of central auditory circuits underlies many forms of tinnitus [26]. Moreover, signs of abnormal activity were not only revealed in the central auditory system but also in non-auditory areas, including the limbic system []. The annoyance of tinnitus is not correlated with its acoustic characteristics, but there is a significant correlation with psychological symptoms [30]. The autonomic nervous system is a major factor in the difference between simply perceiving tinnitus and being distressed by it [31]. Studies have reported that tinnitus distress correlated positively with sympathetic markers and negatively with parasympathetic markers [32,33]. Accumulating evidence illustrates that tinnitus is correlated with symptoms of distress, such as emotional stress and depression for the important role of the limbic system in the pathophysiology of tinnitus, which is based on the further understanding of auditory-limbic interactions [].

Vagal nerve stimulation was developed based on this growing understanding of tinnitus. It may work by activating the nucleus of the solitary tract, which, in turn, may activate the locus coeruleus and nucleus basalis, which release neuromodulators that have significant effects on learning and memory and in plasticity regulation by modulating neurons in the cortex, hippocampus, and amygdala [26]. Engineer and colleagues [8] have indicated that cervical VNS paired with specific auditory stimuli completely eliminated the physiological and behavioral correlates of the phantom sound. They observed that pairing tones with VNS significantly acutely increased excitability and suppressed spontaneous multi-unit activity in rat auditory cortex [37]. Indeed, beneficial effects in relieving psychological symptoms have been confirmed in patients with tinnitus using invasive VNS pairing tones [21] or transcutaneous VNS paired with tones [19,38] in recent small sample pilot studies. However, another experiment also demonstrated that VNS-directed long-lasting reversal of pathological neural plasticity is driven by the repeated association of VNS with tones, and not by VNS alone [8]. German researchers [14] claimed that no clinically relevant improvement of tinnitus complaints was observed after transcutaneous VNS alone. To some extent, this may confirm the suggestion that stimulation at ABVN might prove less effective than VNS because fibers from the auricular branch do not primarily target the nucleus of the solitary tract and so only target it partly. Otherwise, as these researchers themselves suggested [14], the most probable explanation is that VNS alone is not effective in reducing tinnitus, which is supported by the work of Engineer et al. [8]. While sound stimulus alone, as a common sensory exposure treatment strategy, has been applied to treat tinnitus for many years [39,40], studies have indicated that it has only provided some temporary relief [41,42]. Therefore, to identify whether ABVN or the combination of ABVN and sound stimulus plays a more important role in relieving tinnitus, we designed this four-armed novel trial to determine their specific effect on tinnitus.

Acupuncture is an important part of traditional Chinese medicine. It has been accepted in China for thousands of years and is now used as an alternative and complementary medical therapy in Western countries. Meta-analysis results have indicated that acupuncture or acupuncture combined with other therapies is superior to medication alone or non-acupuncture treatments in treating subjective tinnitus [43]. However, in another systematic review, acupuncture for the treatment of tinnitus has not been demonstrated to be efficacious [44]. Whether acupuncture is effective or not in the treatment of tinnitus is a question worthy of discussion. According to the theory of traditional Chinese medicine, the shaoyang meridians of the hand and foot travel to the ear region, so acupoints of the shaoyang meridians located both in local and distant areas of the ear are used to treat tinnitus in this protocol. In addition, the specific acupoints Yifeng (TE17), Tinghui (GB2), Xiaxi (GB43), and Zhongzhu (TE3) are usually chosen in treating tinnitus.

Auricular acupuncture, as an important branch of acupuncture, has also been utilized in the treatment of diseases for years. In ancient China’s earliest medical text Huang Di Nei Jing, which was compiled in the 5th century BC, the correlation between the external ear and the body or viscera is described. In , Dr. Paul Nogier, a physician in France, first originated the concept of an inverted fetus map on the external ear [45]. He proposed a theory that there is a somatotopic and viscerotopic representation on the auricle [46]. According to these theories, disorders from a particular part of the body or viscera can be treated by the corresponding points in the ear [46,47]. Therefore, related auricular acupoints such as Kidney (CO10), Yidan (CO11), or Liver (CO12) are usually selected to treat tinnitus, which, according to the organ-viscera theory of traditional Chinese medicine, results from insufficient Kidney qi or dampness-heat of the Liver and Gallbladder. The Shenmen point (TF4) has the effect of tranquilizing the mind [48,49]. It is often utilized to remedy mental illnesses or psychiatric disorders, such as insomnia [50], anxiety [51,52], or tinnitus [53]. However, the physiological mechanisms associated with these auricular acupoints remain unclear. In this study, it is proposed that the autonomic and the central nervous system could be modified by auricular vagal stimulation via projection from the ABVN to the nucleus of the solitary tract [54], which might work through the neuromodulator system, thus directing plasticity to treat tinnitus.

However, our study has several potential limitations. First, all the outcome measures are self-assessments instead of objective measures. To some extent, objective measures carry out relatively convincing evidence. However, the Tinnitus Handicap Inventory [55,56], visual analogue scale [56], and Hospital Anxiety and Depression Scale [57] have been much used in most of the randomized controlled trials on tinnitus and they are proved to be efficient in reflecting the subjective emotional changes related to tinnitus. Second, this trial is single-blind, therefore, the subjective factors from therapists might bias the outcome assessments. However, it is hard to blind the therapists, who are required to be familiar with treatments for the specific grouping assignment. Another limitation concerns the fact that this is a single center study. It does not lend results to great generalizability to more diverse sets of patients in more diverse regions. In addition, the sample size in this study is relatively small. A large sample, multicenter, and objective measures to assess the effectiveness of treatment should be included in a future study.

Trial status

This trial is currently recruiting participants.

Consent

Written informed consent was obtained from the participants for publication of this manuscript and accompanying images. A copy of the written consent is available for review by the editor-in-chief of this journal.

Abbreviations

Auricular branch of vagus nerve

Vagus nerve stimulation

References

  1. 1.

    Negrila-Mezei A, Enache R, Sarafoleanu C. Tinnitus in elderly population: clinic correlations and impact upon QoL. J Med Life. ;–6.

    CASPubMedPubMed Central Google Scholar

  2. 2.

    Gilles A, De Ridder D, Van Hal G, Wouters K, Kleine Punte A, Van de Heyning P. Prevalence of leisure noise-induced tinnitus and the attitude toward noise in university students. Otol Neurotol. ;–

    PubMed Google Scholar

  3. 3.

    Tyler RS, Baker LJ. Difficulties experienced by tinnitus sufferers. J Speech Hear Disord. ;–4.

    CASArticlePubMed Google Scholar

  4. 4.

    Dobie RA. A review of randomized clinical trials in tinnitus. Laryngoscope. ;–

    CASArticlePubMed Google Scholar

  5. 5.

    Langguth B, Elgoyhen AB. Current pharmacological treatments for tinnitus. Expert Opin Pharmacother. ;–

    CASArticlePubMed Google Scholar

  6. 6.

    Shiozawa P, da Silva ME, de Carvalho TC, Cordeiro Q, Brunoni AR, Fregni F. Vagus nerve stimulation in the treatment of epilepsy. Arq Neuropsiquiatr. ;–7.

    ArticlePubMed Google Scholar

  7. 7.

    Grimm S, Bajbouj M. Efficacy of vagus nerve stimulation in the treatment of depression. Expert Rev Neurother. ;–

    CASArticlePubMed Google Scholar

  8. 8.

    Engineer ND, Riley JR, Seale JD, Vrana WA, Shetake JA, Sudanagunta SP, et al. Reversing pathological neural activity using targeted plasticity. Nature. ;–4.

    ArticlePubMedPubMed Central Google Scholar

  9. 9.

    Schnupp J. Auditory neuroscience: how to stop tinnitus by buzzing the vagus. Curr Biol. ;–5.

    Article Google Scholar

  10. Nomura S, Mizuno N. Central distribution of primary afferent fibers in the Arnold’s nerve (the auricular branch of the vagus nerve): a transganglionic HRP study in the cat. Brain Res. ;–

    CASArticlePubMed Google Scholar

  11. Mei ZG, Zhu B, He W, Gao XY. Morphological basis of auricular acupuncture effects: evidences from neural tracer method of HRP. Lishizhen Med Mater Med Res. ;–7.

    Google Scholar

  12. Kraus T, Hösl K, Kiess O, Schanze A, Kornhuber J, Forster C. BOLD fMRI deactivation of limbic and temporal brain structures and mood enhancing effect by transcutaneous vagus nerve stimulation. J Neural Transm. ;–

    CASArticlePubMed Google Scholar

  13. Polak T, Markulin F, Ehlis AC, Langer JB, Ringel TM, Fallgatter AJ. Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm. ;–

    ArticlePubMed Google Scholar

  14. Kreuzer PM, Landgrebe M, Resch M, Husser O, Schecklmann M, Geisreiter F, et al. Feasibility, safety and efficacy of transcutaneous vagus nerve stimulation in chronic tinnitus: an open pilot study. Brain Stimul. ;–9.

    Google Scholar

  15. Kilgard MP, Vazquez JL, Engineer ND, Pandya PK. Experience dependent plasticity alters cortical synchronization. Hear Res. ;–9.

    Article Google Scholar

  16. Cheng XN. Chinese acupuncture and moxibustion. Beijing: Foreign Language Press;

    Google Scholar

  17. Peuker ET, Filler TJ. The nerve supply of the human auricle. Clin Anat. ;–7.

    ArticlePubMed Google Scholar

  18. Zheng XY. Guiding principles of clinical study on new drugs of traditional Chinese medicine. Beijing: China Medical Science Press;

    Google Scholar

  19. Mei ZG, Yang SB, Cai SJ, Lei HP, Zhuo C, Guo YH, et al. Treatment of tinnitus with electrical stimulation on acupoint in the distribution area of ear vagus nerve combining with sound masking: randomized controlled trial. World J Acupunct-Moxibustion. ;–5.

    Article Google Scholar

  20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. ;–

    CASArticlePubMed Google Scholar

  21. De Ridder D, Vanneste S, Engineer ND, Kilgard MP. Safety and efficacy of vagus nerve stimulation paired with tones for the treatment of tinnitus: a case series. Neuromodulation. ;–9.

    ArticlePubMed Google Scholar

  22. Liu JP. Sample size calculation in clinical research. Zhongguo Zhong Xi Yi Jie He Za Zhi. ;–8.

    Google Scholar

  23. Ernst E, White AR. Prospective studies of the safety of acupuncture: a systematic review. Am J Med. ;–5.

    CASArticlePubMed Google Scholar

  24. Gupta D, Verma S, Vishwakarma SK. Anatomic basis of Arnold’s ear-cough reflex. Surg Radiol Anat. ;–

    CASArticlePubMed Google Scholar

  25. Thakar A, Deepak KK, Kumar SS. Auricular syncope. J Laryngol Otol. ;–7.

    CASArticlePubMed Google Scholar

  26. Engineer ND, Møller AR, Kilgard MP. Directing neural plasticity to understand and treat tinnitus. Hear Res. ;–

    ArticlePubMed Google Scholar

  27. Langguth B, Eichhammer P, Kreutzer A, Maenner P, Marienhagen J, Kleinjung T, et al. The impact of auditory cortex activity on characterizing and treating patients with chronic tinnitus-first results from a PET study. Acta Otolaryngol Suppl. ; 84–8.

  28. Leaver AM, Renier L, Chevillet MA, Morgan S, Kim HJ, Rauschecker JP. Dysregulation of limbic and auditory networks in tinnitus. Neuron. ;–

    CASArticlePubMedPubMed Central Google Scholar

  29. Langguth B, Schecklmann M, Lehner A, Landgrebe M, Poeppl TB, Kreuzer PM, et al. Neuroimaging and neuromodulation: complementary approaches for identifying the neuronal correlates of tinnitus. Front Syst Neurosci. ;

    ArticlePubMedPubMed Central Google Scholar

  30. Luxon LM. Tinnitus: its causes, diagnosis, and treatment. BMJ. ;–1.

    CASArticlePubMedPubMed Central Google Scholar

  31. Jastreboff PJ, Hazell JW. Tinnitus retraining therapy: implementing the neurophysiological model. Cambridge: Cambridge University Press;

    Book Google Scholar

  32. Datzov E, Danev S, Haralanov H, Naidenova V, Sachanska T, Savov A. Tinnitus, heart rate variability, and some biochemical indicators. Int Tinnitus J. ;–3.

    CASPubMed Google Scholar

  33. van der Loo E, Congedo M, Vanneste S, Van De Heyning P, De Ridder D. Insular lateralization in tinnitus distress. Auton Neurosci. ;–4.

    ArticlePubMed Google Scholar

  34. Kraus KS, Canlon B. Neuronal connectivity and interactions between the auditory and limbic systems: effects of noise and tinnitus. Hear Res. ;–

    ArticlePubMed Google Scholar

  35. Rauschecker JP, Leaver AM, Mühlau M. Tuning out the noise: limbic-auditory interactions in tinnitus. Neuron. ;–

    CASArticlePubMedPubMed Central Google Scholar

  36. Landgrebe M, Langguth B, Rosengarth K, Braun S, Koch A, Kleinjung T, et al. Structural brain changes in tinnitus: grey matter decrease in auditory and non-auditory brain areas. Neuroimage. ;–8.

    ArticlePubMed Google Scholar

  37. Nichols JA, Nichols AR, Smirnakis SM, Engineer ND, Kilgard MP, Atzori M. Vagus nerve stimulation modulates cortical synchrony and excitability through the activation of muscarinic receptors. Neuroscience. ;–

    CASArticlePubMed Google Scholar

  38. Lehtimäki J, Hyvärinen P, Ylikoski M, Bergholm M, Mäkelä JP, Aarnisalo A, et al. Transcutaneous vagus nerve stimulation in tinnitus: a pilot study. Acta Otolaryngol. ;–

    ArticlePubMed Google Scholar

  39. Vernon JA. Attempts to relieve tinnitus. J Am Audiol Soc. ;–

    CASPubMed Google Scholar

  40. Hobson J, Chisholm E, El Refaie A. Sound therapy (masking) in the management of tinnitus in adults. Cochrane Database Syst Rev. ;11, CD doi/

    PubMed Google Scholar

  41. Okamoto H, Stracke H, Stoll W, Pantev C. Listening to tailor-made notched music reduces tinnitus loudness and tinnitus-related auditory cortex activity. Proc Natl Acad Sci U S A. ;–

    CASArticlePubMed Google Scholar

  42. Reavis KM, Rothholtz VS, Tang Q, Carroll JA, Djalilian H, Zeng FG. Temporary suppression of tinnitus by modulate sounds. J Assoc Res Otolaryngol. ;–

    ArticlePubMedPubMed Central Google Scholar

  43. Ma WH, Zhang DQ, Wang ZJ, Mei ZG. Meta-analysis on domestic and overseas acupuncture treatment for nervous tinnitus. Chin J Inf Tradit Chin Med. ;–

    Google Scholar

  44. Park J, White AR, Ernst E. Efficacy of acupuncture as a treatment for tinnitus: a systematic review. Arch Otolaryngol Head Neck Surg. ;–

    CASArticlePubMed Google Scholar

  45. Nogier P. From acuriculotherapy to auriculomedicine. Sainte-Ruffine: Maisonneuve, France;

    Google Scholar

  46. Nogier P. Points reflexes auriculares. Maisonneuve, France: Moulins-les-Metz;

    Google Scholar

  47. Oleson TD, Kroening RJ, Bresler DE. An experimental evaluation of auricular diagnosis: the somatotopic mapping or musculoskeletal pain at ear acupuncture points. Pain. ;–

    CASArticlePubMed Google Scholar

  48. O’Connor J, Benksy D. (translator, editor). Acupuncture: a comprehensive text - Shanghai College of Traditional Medicine. Chicago: Eastland;

    Google Scholar

  49. Oleson T, Kroening RA. A comparison of Chinese and Nogier acupuncture points. Am J Acupunct. ;–

    Google Scholar

  50. Jiang B, Ma ZH, Zuo F. Auricular acupuncture for insomnia: a randomized controlled trial. Zhonghua Liu Xing Bing Xsue Za Zhi. ;–2.

    Google Scholar

  51. Wang SM, Kain ZN. Auricular acupuncture: a potential treatment for anxiety. Anesth Analg. ;–

    CASArticlePubMed Google Scholar

  52. Wang SM, Peloquin C, Kain ZN. The use of auricular acupuncture to reduce preoperative anxiety. Anesth Analg. ;–

    CASArticlePubMed Google Scholar

  53. Tao L. Auricular acupuncture combined with body acupuncture for 30 cases of tinnitus. Hunan J Tradit Chin Med. ;

    Google Scholar

  54. He W, Wang X, Shi H, Shang H, Li L, Jing X, et al. Auricular acupuncture and vagal regulation. Evid Based Complement Alternat Med. doi//

  55. Zeman F, Koller M, Langguth B, Landgrebe M. Tinnitus Research Initiative database study group. Which tinnitus-related aspects are relevant for quality of life and depression: results from a large international multicentre sample. Health Qual Life Outcomes. ;

    ArticlePubMedPubMed Central Google Scholar

  56. Figueiredo RR, Azevedo AA, Oliveira PM. Correlation analysis of the visual-analogue scale and the Tinnitus Handicap Inventory in tinnitus patients. Braz J Otorhinolaryngol. ;–9.

    ArticlePubMed Google Scholar

  57. Zöger S, Svedlund J, Holgers KM. The Hospital Anxiety and Depression Scale (HAD) as a screening instrument in tinnitus evaluation. Int J Audiol. ;–

    ArticlePubMed Google Scholar

Download references

Acknowledgements

The study was supported by the general scientific research project of traditional Chinese medicine approved by the Health and Family Planning Commission of Hubei Province, P.R. China.

Author information

Author notes

Affiliations

  1. Medical College of China Three Gorges University, No. 8, University Avenue, Yichang, Hubei, China

    Tian-Tian Li, Zhao-Jun Wang, Shi-Zhong Zhang, San-Jin Cai, Wen-Han Ma, Ding-Qi Zhang & Zhi-Gang Mei

  2. Yichang Hospital of Traditional Chinese Medicine, Clinical Medical College of Traditional Chinese Medicine, China Three Gorges University, Yichang, Hubei, , China

    Song-Bai Yang, Jun-Hong Zhu, San-Jin Cai & Zhi-Gang Mei

Sours: https://trialsjournal.biomedcentral.com/articles//s
Vagus Nerve Massage For Stress And Anxiety Relief

It is unlikely that one of her girlfriends will go broke on such a gift. Liza was beautiful in her new dress, which her mother bought her for her birthday after receiving vacation pay before leaving for the resort. His gift made a pleasant impression on Lisa. Seeing the French perfume, she squealed like a child with joy and, throwing herself on Seryozhka's neck, kissed him.

Blushing in embarrassment, he looked at her laughing friends in confusion.

You will also be interested:

Tell me everything. - In general, when I turned 18, my friend Misha raped me. After I got pregnant, they decided to marry me. I had to.



1722 1723 1724 1725 1726